Pharmaceuticals

Research Press Releases in Pharmaceuticals

Robot as a Service (RaaS) Market
March, 2023

Robot as a Service (RaaS) Market to Reach US$ 59.1 Bn by 2032, driven by growing demand for professional robots in a several industries: Global Insight Services

New York, March 2022: According to a new research study by Global Insight Services (GIS), the global Robot as a Service (RaaS) Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 59.1 Billion by 2032.

Robot as a Service (RaaS) is a cloud services unit that enables the seamless integration of robots and embedded devices into online and cloud computing environments. Customers and robotic enterprises both gain from robots as a service. Robots as a service enable businesses to reap the rewards of robotic process automation (RPA) by licensing robotic gear and utilizing a cloud-based subscription service. The key advantage of employing this technology is that it reduces the need for manual IT support while increasing the efficiency of robotic procedures. The deployment of a robot as a service in an organization is dependent on three factors: first, the use of proper tools to operate the robot as a service; second, determining the precise level of services needed by the company; and third, selecting a vendor to assist the robot as a service.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10534/

The growing need for professional robots in several sectors is predicted to boost the worldwide robot as a service market expansion during the forecast period. This is due to the growing demand for automated operations across a wide range of professional fields. Due to an increase in the impact of human assistance tasks, reduction of work pressure, and support of maximum reliability in repetitive activities in industries, RaaS is gaining popularity. The RaaS market is growing due to high demand for RaaS to monitor, control, and manage other activities in the food and beverages, defense, logistics, and other manufacturing sectors. Increased automation in manufacturing facilities to boost productivity is expected to boost the growth of global RaaS market.

Robot as a Service (RaaS) Market: Restraints & Challenges

Service robots have a high annual maintenance cost, which limits firms’ ability to invest, particularly small and medium-sized businesses. This is anticipated to stifle market expansion shortly. The market’s growth is projected to be limited by organizations’ unwillingness to migrate from manual to automated operations. Companies are using RPA solutions all over the world to optimize business operations. However, a lack of understanding of the technology is preventing RaaS from being adopted. Within the next two to three years, professional service providers plan to use RPA technologies in their organization.

Robot as a Service (RaaS) Market Report Findings

https://www.globalinsightservices.com/reports/robots-as-a-service-raas-market/

The professional robots segment is likely to hold a dominant Robot as a Service (RaaS) Market share and grow at a substantial CAGR during the forecast period.

By service, the market is divided into personal and professional. The professional robots category has a bigger market share and is predicted to increase at an exponential rate throughout the forecast period. This is mostly due to increased demand for service robots in areas such as defense, construction, medical, logistics, and others.

The logistics segment is anticipated to hold a majority of the Robot as a Service (RaaS) Market size throughout the study period.

By end-user, the market is classified into healthcare, BFSI, food & beverage, IT & telecom, retail, defense, media & entertainment, logistics, and others. Because of the automation brought by the act of moving and storing goods, the logistics segment has the largest stake. In addition, there is a growing need for service robots in order to streamline supply chain procedures across sectors. Medical service robots are expected to develop significantly as people turn toward incorporating robotic solutions for important medical procedures and with the advent of high-tech research facilities.

The Europe region is estimated to exhibit the highest growth rate during the Robot as a Service (RaaS) Market forecast period.

Europe dominates the global robot as a service market, owing to increased demand for personal and professional robots in numerous nations throughout the region. Europe has the highest concentration of manufacturers, at approximately 44 percent, due to rising demand from industries such as defense, medical, logistics, and retail. Following Europe, Asia Pacific held the second-largest share and is expected to grow at the fastest rate.

This is primarily due to increased R&D activity in the industrial robot industry, as well as increased government funding in robotics, automation, artificial intelligence, and other technologies. According to World Robotics 2018, over 35% of service robot manufacturers are present in North America, raising the potential growth of the market.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10534

Competitive Landscape

The key players in the market are KUKA AG, Parrot SA, Lely International, DJI, Northrop Grumman, Intuitive Surgical, Inc., Aethon Inc., Kongberg Maritime AS, Honda Motor Co. Ltd., and iRobot Corporation., among others.

Recent Developments in the Robot as a Service (RaaS) Market:

  • In July 2021, ABB purchased the ASTI Mobile Robotics Group in order to accelerate the development of flexible automation employing mobility devices. The acquisition strengthens the company’s Robotics and Machine Automation solutions, enabling it to offer a unique automation portfolio and expand into new business areas.
  • In April 2021, Panasonic Corporation has released a systematic model of their Walk Training Robot, which is intended to provide effective and safe walking training for older people. In addition, the company provides a robot-assisted solution to hospitals, institutions, and other organizations.

Robot as a Service (RaaS) Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Robot as a Service (RaaS) Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Robot as a Service (RaaS) Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Robot as a Service (RaaS) Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Robot as a Service (RaaS) Market Segmentation

By Services

  • Personal
  • Professional Others

By End-user

  • Healthcare
  • BFSI
  • Food & beverage
  • IT & Telecom
  • Retail
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • KUKA AG
  • Parrot SA
  • Lely International
  • DJI
  • Northrop Grumman
  • Intuitive Surgical, Inc.
  • Aethon Inc
  • Kongberg Maritime AS
  • Honda Motor Co. Ltd
  • iRobot Corporation
Read More

Laryngoscopes Market
March, 2023

Laryngoscopes Market to Reach US$ 1.5 Bn by 2032, driven by new product launches and strategic activities by major players: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Laryngoscopes Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 1.5 Billion by 2032.

Laryngoscopy is a medical device used in the visualization and examination of larynx. It is also used during tracheal intubation in patients requiring ventilator support and compose of blades, light source and handle. The two forms of laryngoscopy procedure are direct laryngoscopy and indirect laryngoscopy.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10533

Laryngoscopes Market: Key Trends and Drivers

Increasing disease burden of laryngeal diseases as well as infectious and chronic respiratory diseases in developing countries is a major factor contributing to the laryngoscopes market share. Laryngeal cancer is second most common respiratory cancer, and incidence rate of laryngeal cancer is rising majorly due to adoption of unhealthy lifestyle and increased consumption of alcohol and tobacco. According to the Centers for Disease Control and Prevention, in U.S. about 40 million adults smoke cigarettes, and around 4.7 million middle and high school students consume at least one tobacco product. Thus, increasing adult smoking rates and tobacco consumption has led to several laryngeal diseases. Additionally, according to the American Society of Clinical Oncology (ASCO), approximately 184,615 individuals were diagnosed with laryngeal cancer globally. Hence, increasing demand for laryngoscopes to treat such diseases will accelerate the industry growth in forecast period.

Laryngoscopes Market: Restraints & Challenges

The market growth is limited by the strict regulations imposed on these devices. Additionally, high cost of these devices is another aspect that is expected to limit the industry growth. Furthermore, miniaturization of newly developed fiber optic laryngoscope could generate numerous growth opportunities for the market in the coming years.

Laryngoscopes Market Report Findings

https://www.globalinsightservices.com/reports/laryngoscopes-market/

The Video Laryngoscopes segment is likely to hold a dominant Laryngoscopes Market share and grow at a substantial CAGR during the forecast period.

Based on product, the market is bifurcated into Fiber Optic Laryngoscopes, Video Laryngoscopes, and Standard/Conventional Laryngoscopes. Video laryngoscopes segment is estimated to grow at xx% CAGR over the anticipated time period. Growing awareness about advantages associated with use of video laryngoscopes over conventional laryngoscopes will foster the market demand. The advantages include enhanced laryngeal view, reduction in applied force, and higher rates of successful rescue after the failure of direct laryngoscopy. Additionally, video laryngoscopes reduce errors during intubation and improves learning, feedback for a patient being put on ventilator.

The reusable segment is anticipated to hold a majority of the Laryngoscopes Market size throughout the study period.

Based on the usability, the market is bifurcated into Reusable, and Single-use. Laryngoscopes market from reusable segment was accounted for more than USD xx million in 2022. Reusability of devices is an important factor influencing medical professionals’ and hospitals’ purchasing decisions. These devices are highly preferred due to more functionality than traditional laryngoscopes and ease of use. On the other hand, reusable laryngoscopes, are more expensive up front but do not need to be replaced as frequently.

The hospital segment is anticipated to hold a majority of the Laryngoscopes Market size throughout the study period.

Based on the end-use, the market is bifurcated into specialty clinics, hospitals, and others. The hospital segment held over xx% revenue share in 2022, owing to expanding number of hospitals among developing and developed countries. Additionally, availability of advanced video laryngoscopes and enhanced visualization is likely to contribute to the segment demand. With high penetration of hospitals and presence of healthcare professionals will bolster the laryngoscopes market progression.

The Europe region is estimated to exhibit the highest growth rate during the Laryngoscopes Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Europe laryngoscopes market exceeded USD xx million in 2022 and is predicted to witness enormous growth during analysis timeframe due to rising prevalence of respiratory diseases among geriatric population as well as in adults. Increasing consumption of tobacco, smoking and rising air pollution are some factors that trigger respiratory diseases. Moreover, increasing number of healthcare initiatives by several government and non-government organization in the region will accelerate the regional market growth.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10533

Competitive Landscape

The global Laryngoscopes Market report includes players are KARL STORZ GmbH & Co, Ambu A/S, Medtronic plc, Flexicare Medical, Penlon Limited, Rudolf Riester GmbH, Propper Manufacturing Co. Inc., Teleflex Incorporated, Verathon Inc, Venner Medical, Olympus Corporation, among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In November 2022, PROACT Medical launched an innovative new range of gas sampling lines along with their new line of single-use laryngoscopes in the European market.
  • In July 2022, Zsquare, a leading developer of high-performance, single-use endoscopes, announced that it received FDA clearance to market its first product, the Zsquare ENT-Flex Rhinolaryngoscope.

Laryngoscopes Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Laryngoscopes Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Laryngoscopes Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Laryngoscopes Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Laryngoscopes Market Segmentation

By Product

  • Fiber Optic Laryngoscopes
  • Video Laryngoscopes
  • Standard/Conventional Laryngoscopes

By Usability

  • Reusable
  • Single-use

By End-use

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • KARL STORZ GmbH & Co
  • Ambu A/S
  • Medtronic plc
  • Flexicare Medical
  • Penlon Limited
  • Dodow (LIVLAB)
  • Rudolf Riester GmbH
  • Propper Manufacturing Co. Inc
  • Teleflex Incorporated
  • Verathon Inc,

 

Read More

Sleep Tech Devices Market
March, 2023

Sleep Tech Devices Market to Reach US$ 95.8 Bn by 2032, driven by high prevalence of sleep disorders is expected to increase the demand for sleep tech devices: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Sleep Tech Devices Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 95.8 Billion by 2032.

Sleep tech devices are designed for monitoring and improving the outcome in patients with sleep disorders such as sleep apnea, insomnia, narcolepsy, etc.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10532/

Sleep Tech Devices Market: Key Trends and Drivers

Increasing technological advancements in sleep trackers is one of the significant opportunities for the sleep tech devices market growth. Sleep trackers are becoming more sophisticated. For example, 2breathe is a smart device that is supposed to be worn around the waist before going to bed. The device can detect breathing and play tones to aid sleep, and it automatically shuts off when it detects snoozing. It’s linked to an app that shows how one slept every morning. Beddit, on the other hand, is a sleep sensor that consists of a thin rectangle that is placed beneath sleeper sheets. It then monitors a variety of parameters, including sleep, varying sleep stages, respiration rate, heart rate, and more.

Sleep Tech Devices Market: Restraints & Challenges

the market growth is limited by the strict regulations imposed on these devices. Additionally, high cost of these devices is another aspect that is expected to limit the industry growth. Furthermore, miniaturization of newly developed sleep trackers could generate numerous growth opportunities for the market in the coming years.

Sleep Tech Devices Market Report Findings

https://www.globalinsightservices.com/reports/sleep-tech-devices-market/

The non-wearables segment is likely to hold a dominant Sleep Tech Devices Market share and grow at a substantial CAGR during the forecast period.

Based on product, the market is bifurcated into wearables, and non-wearables. Sleep tech devices market from non-wearables segment accounted for xx% business share in 2022 and is set to register a significant CAGR through 2032 driven by growing demand for smart beds. This smart bed can monitor and modify its settings automatically to help sleep soundly all night. It adapts to one sleeping position in real time, gently conforming to side, back, or stomach profiles to make sleeping comfortable. The bed can also help fall asleep faster by warming feet.

The narcolepsy segment is anticipated to hold a majority of the Sleep Tech Devices Market size throughout the study period.

Based on the application, the market is bifurcated into insomnia, obstructive sleep apnea, narcolepsy, and others. Sleep tech devices market from narcolepsy segment held nearly xx% revenue share in 2022. This is owing to the growing cases of narcolepsy. Narcolepsy is a chronic sleep condition that usually begins in adolescence and is characterized by extreme daytime sleepiness with serious repercussions for the patient. According to Journal of Clinical Sleep Medicine the cases of narcolepsy per 100,000 population increased by 14%, i.e., from 38.9 in 2013 to 44.3 in 2016. Such factors are expected to facilitate the demand for sleep tech devices and medication.

The specialty centers segment is anticipated to hold a majority of the Sleep Tech Devices Market size throughout the study period.

Based on the distribution channel, the market is bifurcated into specialty clinics, direct-to-consumer, hospitals, and others. Sleep tech devices market from specialty centers segment will exhibit a CAGR of xx% during the forecast period. The demand for sleep tech devices has surged as the number of patients suffering from sleeping problems has also increased. Sleep difficulties are common among people with psychological illnesses, and often prefer to seek therapy at specialty clinics. Sleep tech devices, such as sleep trackers, are recommended by healthcare professionals working in specialist clinics to boost mental health in individuals. The segment is also likely to rise as people become more aware of sleep therapy sessions.

The Europe region is estimated to exhibit the highest growth rate during the Sleep Tech Devices Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Europe market accounted for the largest revenue share in the global market in 2022. Rising prevalence of sleep disorders in the region, owing to an ageing population and rising cases of depression and insomnia among adults. For instance, according to an NHS Inform research, roughly one in every three persons in the UK suffers with insomnia, that is especially prevalent among the elderly population. Furthermore, high disposable income and presence of leading industry players in the region contributes significantly to the regional business growth..

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10532/

Competitive Landscape

The global Sleep Tech Devices Market report includes players are Casper Sleep Inc., Cadwell Industries Inc., Dreem, Beddit (Apple Inc.), Eight Sleep, Dodow (LIVLAB), Emfit Ltd., Fitbit Inc. (Google LLC), ResMed Inc., Koninklijke Philips N.V., Sleep Shepherd LLC, Oura Health Ltd., Sleepace, Xiaomi, Withings,, among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In May 2022, Huawei Vietnam launched three new generation smartwatches, Huawei Watch GT3 Pro, Watch fit 2 and Watch Kids 4 Pro. This smartwatch is equipped with advanced features such as health alerts, early sleep alerts, medication alerts, and positive mood and exercise volume information.
  • In February 2022, Redmi launched the Redmi Smart Band Pro equipped with features such as an AMOLED display and 50 meters of water resistance. In addition, it has a heart rate monitor and a SpO2 sensor that will enable blood oxygen monitoring and sleep monitoring..

Sleep Tech Devices Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Sleep Tech Devices Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Sleep Tech Devices Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Sleep Tech Devices Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Sleep Tech Devices Market Segmentation

By Product

  • Wearables
  • Non-Wearables

By Application

  • Insomnia
  • Obstructive Sleep Apnea
  • Narcolepsy
  • Others

By Distribution Channel

  • Specialty Clinics
  • Direct-to-Consumer
  • Hospitals
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Casper Sleep Inc
  • Cadwell Industries Inc.
  • Dreem
  • Beddit (Apple Inc.)
  • Eight Sleep
  • Dodow (LIVLAB)
  • Emfit Ltd.
  • Fitbit Inc. (Google LLC)
  • ResMed Inc.
  • Koninklijke Philips N.V.

 

Read More

Medical Equipment Financing Market
March, 2023

Medical Equipment Financing Market to Reach US$ 311.9 Bn by 2032, driven by rapid technological advancements combined with AI technology has leveraged the medical industry potential: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Medical Equipment Financing Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 311.9 Billion by 2032.

The need of time is staying up to date with advancements in medical equipment but it can be an expensive prospect. That’s why many health care professionals need medical equipment financing to obtain the tools and machines they need. A medical equipment loan or lease helps those professionals get the equipment they need to bring in new and returning patients, helping them increase cash flow and build their reserves. With the continuous advancement in medical technology, it has become a necessity to opt for the best-in-class medical equipment for excellent healthcare services. However, advanced diagnostic systems are expensive and are difficult for medical practitioners and hospitals to afford through their funds. There arises the need for medical equipment funding with low monthly instalments and flexible loan models.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10531/

Medical Equipment Financing Market: Key Trends and Drivers

Increasing acceptance of artificial intelligent technology has leveraged the medical industry potential. With this, there is an upgradation to new equipment with better features that provides superior treatment to the patients. For instance, according to the Equipment Leasing & Finance Foundation’s Report, in 2019, nearly 8 in 10 businesses that acquired equipment and software used at least one form of financing such as lease, secure loan, or line of credit. Therefore, acquiring medical equipment with medical equipment loans and leases has been made simple and easy.

Medical Equipment Financing Market: Restraints & Challenges

As their economies expand, equipment finance firms continue to face numerous challenges. Even while banks have more resources and are seeking chances in the medical equipment market, the majority of businesses have grown more capital-conscious. It is more likely that hospitals, clinics, and diagnostic centers will spend money to maintain their existing equipment than to purchase new ones..

Medical Equipment Financing Market Report Findings

https://www.globalinsightservices.com/reports/medical-equipment-financing-market/

The patient monitoring equipment segment is likely to hold a dominant Medical Equipment Financing Market share and grow at a substantial CAGR during the forecast period.

Based on equipment, the market is bifurcated into diagnostics equipment, therapeutic equipment, patient monitoring equipment, laboratory equipment, and medical furniture. Among these, the patient monitoring equipment segment exceeded USD xx billion in 2022. This is attributed to the increasing demand for patient monitoring equipment in developing countries to observe, report and analyze acute or chronic conditions used in hospitals and clinics. Additionally, increasing use of ECG devices to check heart’s rhythm and electrical activity will propel overall medical equipment financing market expansion. Furthermore, high availability of patient monitoring equipment in the market such as blood pressure monitors, electro-cardiograph (ECG) device, patient monitors, pulse oximeter, pulse watches, continuous glucose monitoring device, spirometers, and capnography, among others. This will fuel the market progression. Therefore, many firms incline towards medical equipment financing & leasing, and loans required for infrastructure.

The new medical equipment segment is anticipated to hold a majority of the Medical Equipment Financing Market size throughout the study period.

Based on the type, the market is bifurcated into new medical equipment, rental equipment, and refurbished equipment. Among these, new medical equipment segment surpassed USD xx billion in 2022. This is owing to adoption of artificial intelligence, blockchain, voice search, chatbots, and virtual reality in health technologies. Moreover, increasing costs of the medical equipment’s, leading doctors or healthcare firms incline towards loan to purchase an equipment, this also reduces the high interest rates regardless of any type and number of instruments. In addition, it also helps in preserving working capital and streamline operations in a modified manner. Therefore, growing adoption of new medical equipment will foster the overall market size.

The Hospital segment is anticipated to hold a majority of the Medical Equipment Financing Market size throughout the study period.

Based on the end-user, the market is bifurcated into hospitals, clinics, laboratories & diagnostic centers, and ambulatory surgical centers [ASCs]. Medical equipment financing market from hospital segment accounted for xx% business share in 2022 and is set to register a significant CAGR through 2032. This is due to the rising utilization of medical equipment financing practices that allows hospitals to purchase medical equipment at lower price. Similarly, equipment financing increases the working capital of hospitals with more available capital. This allows hospitals in hiring new doctors and clinicians along with investment in cybersecurity software. Moreover, hospitals prefer to opt for healthcare loan including infrastructure loan and working capital to avoid risks in the market. Thus, medical equipment financing reduces the risk and controls the overall financial situations. As a result, increased hospital investments around the globe will certainly have a positive impact on the industry growth.

The North America region is estimated to exhibit the highest growth rate during the Medical Equipment Financing Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Europe medical equipment financing market is expected to grow at xx% CAGR during the forecast period driven by the high cost of healthcare equipment. According to the Organization for Economic Co-operation and Development (OECD), in Europe, the healthcare spending per capita increased around 3% each year between 2013 and 2019 by adjusting the inflation. Similarly, growing demand for medical equipment financing coupled with presence of major market player including Meridian Group International, and Societe Generale S.A will accelerate the regional market trends..

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10531/

Competitive Landscape

The global Medical Equipment Financing Market report includes players are CMS Funding, Kabbage (American Express), Bajaj Finserv, TIAA Bank, Blue Bridge Financial, LLC, First American Healthcare Finance, HDFC Bank, HeroFinCorp, JPMorgan Chase & Co., National Funding, SMC Finance, Truist Bank, Societe Generale S.A., and Toronto-Dominion Bank., among others.

Recent Developments in the Market:

  • In February 2022, Toronto-Dominion Bank and First Horizon announced the signing of a new contract that will allow Toronto-Dominion Bank to completely acquire First Horizon. The deal is worth USD 13 billion and will help TD strengthen its hold in the global market
  • In December 2021, API Holdings Limited and Piramal Capital & Housing Finance entered a joint collaboration in which the latter will offer its digital platform Retailio to API Holding. This will allow the company to improve its financial assistance services to all stakeholders.
  • In July 2021, IFC and the Multilateral Investment Guarantee Agency (MIGA) launched a trade finance guarantee initiative to help low-income countries recover from the effects of the pandemic by supporting trade flows of critical goods, including food and medical equipment.
  • In May 2021, E. Healthcare and NSIA Banque Cote d’Ivoire announced a partnership with IFC’s Africa Medical Equipment Facility to strengthen the healthcare industry and support medical equipment financing across Africa.
  • In April 2021, IMAGEENS jointly raised $1.45 million in seed funding with Anaxago. This is expected to strengthen the company’s team with key R&D talent to expand the deployment of software solutions.

Medical Equipment Financing Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Medical Equipment Financing Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Medical Equipment Financing Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Medical Equipment Financing Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Medical Equipment Financing Market Segmentation

By Equipment

  • Laboratory Equipment
  • Therapeutic Equipment
  • Diagnostics Equipment
  • Patient Monitoring Equipment
  • Medical Furniture

By Type

  • Refurbished Equipment
  • Rental Equipment
  • New Medical Equipment

By End-usee

  • Hospital
  • Clinics
  • Laborateries &Diagnostic Centers
  • Ambulatory Surgical Centers [ASCs]

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • CMS Funding
  • Kabbage (American Express)
  •  Bajaj Finserv
  • TIAA Bank
  • Blue Bridge Financial, LLC
  • First American Healthcare Finance
  • HDFC Bank
  • HeroFinCorp
  • JPMorgan Chase & Co.
  • National Funding
  • SMC Finance

 

Read More

Compartment Syndrome Monitoring Devices Market
March, 2023

Compartment Syndrome Monitoring Devices Market to Reach US$ 409.7 Million by 2032, driven by increasing investments in research-based projects and growing alliances among leading companies and research centers for drug discovery, and increasing inclination toward next-generation sequencing methods for identifying, treating, and monitoring chronic diseases: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Compartment Syndrome Monitoring Devices Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 409.7 Million by 2032.

The compartment syndrome monitoring devices refer to medical equipment that is employed for monitoring the compartmental pressure that assists in detection of compartment syndrome. These devices are specialized equipment that are increasingly employed in monitoring acute, chronic, and abdominal compartment syndrome.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10530/

Compartment Syndrome Monitoring Devices Market: Key Trends and Drivers

Technological developments in compartment pressure monitoring devices and the advent of a collaborative technique for promoting the operationality & precision of these devices will foster the business landscape. Better understanding of the pathophysiology of compartment syndrome and notable developments in compartment syndrome monitoring devices have improved the diagnosis of compartment syndrome & is expected to reduce the disease morbidity. The application of innovative diagnostic modalities including near-infrared spectroscopy (NIRS), radiofrequency identification (RFID) implants, and biomarker analysis is estimated to fuel the user preference.

The emergence of RFID implants, a novel technology that employs radio frequency electromagnetic waves for transferring data would assist the clinicians. Hence, the RFID sensors are in demand and being used in compartment syndrome monitoring devices. Furthermore, the product development and commercialization by major market players is set to prove beneficial for market growth.

Compartment Syndrome Monitoring Devices Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Compartment Syndrome Monitoring Devices Market Report Findings

https://www.globalinsightservices.com/reports/compartment-syndrome-monitoring-devices-market/

The disposable segment is likely to hold a dominant Compartment Syndrome Monitoring Devices Market share and grow at a substantial CAGR during the forecast period.

Based on Product, the market is bifurcated into Disposables, and Equipment. Disposables segment is anticipated to witness xx% CAGR from 2022 to 2032 due to the rising preference for single-use and disposable equipment. Disposable medical supplies lower the risk concerned with hospital-acquired infection (HAI) by delivering better protection against transmission and contamination. The increasing usage and surged demand for sustainable medical solutions will stimulate the market share.

The Chronic compartment syndrome segment is anticipated to hold a majority of the Compartment Syndrome Monitoring Devices Market size throughout the study period.

Based on the syndrome type, the market is bifurcated into Acute Compartment Syndrome, Chronic Compartment Syndrome, and Abdominal Compartment Syndrome. Chronic compartment syndrome segment surpassed USD xx million in 2022 and is likely to register xx% CAGR from 2022 to 2032. This is owing to the substantial prevalence of chronic compartment syndrome. This is also known as chronic exertional compartment syndrome (CECS) that refers to a condition that majorly occurs due to exertional or repetitive loading activities. CECS is commonly profound among athletes such as long-distance runners, football players, skiers, and basketball players.

The Clinics segment is anticipated to hold a majority of the Compartment Syndrome Monitoring Devices Market size throughout the study period.

Based on the end-use, the market is bifurcated into Hospitals, Clinics, and Others. Clinics segment accounted for xx% revenue share in 2022 and is projected to progress at % CAGR during the forecast period. This is pertaining to the surging preference and steady transition towards clinics. The demand for these healthcare settings is surging with high application rate of novel compartment syndrome monitoring devices. Furthermore, the shift in the preference towards clinics due to several advantages including rapid assistance and cost-effective services have substantially impacted the segment growth. Clinics are regarded as a preferable alternative for preventive care and effective management of chronic conditions as they feature low waiting periods.

The North America region is estimated to exhibit the highest growth rate during the Compartment Syndrome Monitoring Devices Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the North America market accounted for the largest revenue share in the global market in 2022. North America has a large regional market in terms of revenue. The increasing prevalence of genetic and chronic disorders, such as cancer, the aging population, the growing demand for targeted and personalized medicine, and favorable government initiatives are the primary factors behind the growth of the whole-exome sequencing market. According to the HIV.gov updates in October 2022, HIV affects around 1.2 million persons in the United States. In the United States, in 2020, 30,635 persons were diagnosed with HIV. Thus, the growing burden of infectious diseases is expected to increase in demand for its diagnosis, thereby boosting the market’s growth over the forecast period.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10530/

Competitive Landscape

Some of the major players operating in the compartment syndrome monitoring devices industry are Millar, Inc., MY01, Inc., Critical Care Diagnostics (C2DX), Inc., Potrero Medical, Medline Industries, Becton, Dickenson, and Company, and ConvaTec. These players are involved in mergers & acquisitions, partnerships, and distribution agreements to gain competitive advantage over their competitors.

Recent Developments in the Blood-Brain Barrier Market:

  • In September 2022: Potrero Medical received FDA Breakthrough Device Designation for their AKI Predict machine learning algorithm, for the advanced prediction of acute kidney injury (AKI) associated with IAH in cardiac post-surgical intensive care patients.
  • In July 2022: Sentinel Medical Technologies launched TraumaGuard Monitoring Device, a hands-free monitoring device designed to continuously measure real-time IIP and Core Body Temperature (CBT) in critical care patients.
  • In March 2022, C2Dx, another industry leader, announced the acquisition of Hemostatix Medical Technologies LLC, a medical device specialist. The acquisition complemented C2Dx’s plans to enhance the delivery of niche medical products around the world.

Compartment Syndrome Monitoring Devices Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Compartment Syndrome Monitoring Devices Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Compartment Syndrome Monitoring Devices Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Compartment Syndrome Monitoring Devices Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Compartment Syndrome Monitoring Devices Market Segmentation

By Product

  • Disposables
  • Equipment

By Technology

  • Acute Compartment Syndrome
  • Chronic Compartment Syndrome
  • Abdominal Compartment Syndrome

By Application

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Millar, Inc.
  • MY01, Inc.
  • Critical Care Diagnostics (C2DX), Inc.
  • Potrero Medical
  • Medline Industries
  • Boston Scientific Corporation
  • Becton, Dickenson, and Company
  • ConvaTec.
  • Hemostatix Medical Technologies LLC,
  • Biometrix Ltd. (3i Group plc)

 

Read More

Hemostasis Products Market
March, 2023

Hemostasis Products Market to Reach US$ 2.7 Bn by 2032, driven by increase in number of surgeries such as orthopedic surgery, gynecological surgery, reconstructive surgery, and cardiac surgery; rise in in various cancer types that require surgical procedures; and development of new hemostasis product market by large number of key players: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Hemostasis Products Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 2.7 Billion by 2032.

Hemostat is referred to a surgical agent that regulates and controls the bleeding process during surgical procedures. Hemostats help to shorten surgery time and reduces the need for blood transfusion. Hemostatic agents are essential in establishing hemostasis in pre-hospital conditions and preventing death associated with hemorrhage. Hemostats are used to compress blood vessels and prevent the flow of blood or other fluids. They are generally used in adjunct to surgical procedures to manage bleeding. Hemostatic agents offer different benefits, which include decreased wound healing & operative time, better management of anti-coagulated patients, and reduction in the patient recovery period boosting the hemostasis market.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10529/

Hemostasis Products Market: Key Trends and Drivers

Rise in flowable hemostats usage boosts the flowable hemostats market. According to the International Osteoporosis Foundation, in 2019, approximately 200 million people were affected by osteoporosis-related fractures across the globe. Thus, rise in burden of orthopedic disorders increases the demand for hemostats to reduce surgical injuries, which is anticipated to foster the growth of the hemostats market size. Furthermore, rise in geriatric population notably contributes toward the growth of the market. This is attributed to the fact that aged individuals are highly susceptible to various types of diseases, which increases the need for surgeries, thus boosting the hemostats market share. Furthermore, increase in number of road accidents has led to surge in surgical procedures, which augmented the growth of the hemostats market. According to the World Health Organization, in 2019, approximately 235 million major surgical procedures were performed across the globe. According to the National Cancer Statistics, in 2020, there were 1,806,590 new cases of cancer in the U.S. Therefore, surge in number of surgeries is anticipated to boost the growth of the market. According to the American Society of Plastic Surgeons, 15.6 million cosmetic surgeries were performed in 2020. Furthermore, increase in number of product approvals is expected to provide lucrative hemostats market opportunity for the expansion during the hemostats market forecast period. Thus, rise in hemostats utilization in surgeries is bound to increase hemostasis market potential.

Hemostasis Products Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Hemostasis Products Market Report Findings

https://www.globalinsightservices.com/reports/hemostasis-products-market/

The Infusible hemostasis products segment is likely to hold a dominant Hemostasis Products Market share and grow at a substantial CAGR during the forecast period.

Based on Product, the market is bifurcated into Topical Hemostasis Product, Infusible Hemostasis Product, and Advanced Hemostasis Product. Infusible hemostasis products segment surpassed USD xx million in 2021. This is attributable to the growing number of patients suffering from cardiac diseases such as myocardial infarction, coronary heart disease, aortic disease etc. Cardiovascular disease is responsible for majority of deaths in countries such as India. It accounts for more than 25% of total deaths occurring in the country. Thereby, stimulating the product demand.

The Hemostat agents segment is anticipated to hold a majority of the Hemostasis Products Market size throughout the study period.

Based on the application, the market is bifurcated into Trauma, Surgery, Hemophilia, Myocardial Infarction, Thrombosis, and Others. Hemostat agents, such as products containing thrombin, are a safe and effective alternative to gelatin sponges and oxidized cellulose in controlling bleeding during surgeries. Hemostatic agents containing thrombin and collagen are superior to surgical hemostasis alone in controlling microvascular bleeding during cardiac surgery. It is also reasonable to use fibrin sealants as an adjunct to surgical hemostasis to limit bleeding in cardiac and aortic surgery.

As per the research study published in June 2021, titled “German Heart Surgery Report 2020: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery”, a total of 92,809 operations were classified as heart surgery procedures in the classical sense, of which 29,444 were isolated coronary artery bypass grafting procedures, 35,469 were isolated heart valve procedures, and the number of isolated heart transplantations increased by 2% to 340. Additionally, according to the British Heart Foundation’s February 2021 report, about 371,000 heart procedures and operations were performed in England in 2020. Hence, the high number of heart surgeries and operations being performed every year may boost demand for hemostat agents that control bleeding.

The Hospitals segment is anticipated to hold a majority of the Hemostasis Products Market size throughout the study period.

Based on the end-use, the market is bifurcated into Hospitals, Clinics, and Others. The increase in hospital visits and growing expenditures on hospital care can be attributed to the growth of the hospital segment. Hospital spending climbed 6.4% amounting to USD 1,270.1 billion in 2020, the National Health expenditure data sheet states. This was an increase from the 6.3% growth in 2019. Additionally, there were almost 130 million hospital visits in the United States. Few of the well-known market leaders in the global hemostasis products market that are profiled by Research Nester are Pfizer Inc., Integra LifeSciences Corporation, Baxter, Medtronic, Stryker, BD (Becton, Dickinson and Company), Biom’up Innovative Surgery, Johnson & Johnson Services, Inc., CryoLife, Inc., Hemostatis LLC, and others.

The Asia Pacific region is estimated to exhibit the highest growth rate during the Hemostasis Products Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the market growth in Asia Pacific is elevated by rising instances of road accidents followed by rise in blood donations in the region. According to the Ministry of Road Transport & Highways under Government of India, in 2022, the country witnessed 3,66,138 road accidents, leading to 1,31,714 losses of lives and 3,48,279 people injured. 18-45 years’ age group is the prime group caught up in road accidents, which accounts for nearly 70% of total accidental deaths. Furthermore, in Japan, 400 mL blood donations are expected to result in an estimated 1.3 million liters of blood being donated in 2020. Additionally, from 1998 to 2020, blood donation increases by 40 folds in China and in 2020, there were approximately 16 million blood donation in the country.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10529

Competitive Landscape

The global hemostasis products market is moderately fragmented and consists of a number of major players. Companies like Abbott Laboratories, Baxter International, Inc., C. R. Bard, Inc. (BD), CSL Behring LLC, Dexur, Grifols, S.A., Johnson & Johnson, Medtronic plc, Pfizer, Inc., and Tricol Biomedical, among others, hold the substantial market share in the Hemostasis Products market.

Recent Developments in the Blood-Brain Barrier Market:

  • In May 2022, Precision BioLogic Inc., a developer of hemostasis diagnostic products, reported the launch of its new cryocheck Chromogenic Factor IX assay in Canada, the European Union, and the United Kingdom, Australia, and New Zealand.
  • In February 2022, Futura Surgicare Pvt Ltd expanded its product portfolio by launching hemostatic products under the brand Hemostax (Oxidised Regenerated Cellulose) under a new vertical, Dolphin Hemostats. Hemostax Standard is an absorbable hemostat designed to help surgeons control bleeding more efficiently.

Hemostasis Products Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Hemostasis Products Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Hemostasis Products Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Hemostasis Products Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Hemostasis Products Market Segmentation

By Product

  • Topical Hemostasis Product
  • Infusible Hemostasis Product
  • Advanced Hemostasis Product

By Technology

  • Trauma
  • Surgery
  • Hemophilia
  • Myocardial Infarction
  • Thrombosis
  • Others

By Application

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Abbott Laboratories
  • Baxter International, Inc.
  • C. R. Bard, Inc. (BD)
  • CSL Behring LLC
  • Dexur
  • Boston Scientific Corporation
  • Grifols, S.A.
  • OraSure Technologies, Inc.
  • Johnson & Johnson
  • Medtronic plc
  • Pfizer, Inc.
  • Tricol Biomedical
Read More

pH Meters Market
March, 2023

pH Meters Market to Reach US$ 2.4 Bn by 2032, driven by Rising demand for these devices in industries such as food processing, water treatment, power, agriculture, fertilizers, etc.: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global PH Meters Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 2.4 Billion by 2032.

pH meters are instruments that are used to measure hydrogen-ion activity to determine acidic and alkaline levels in solutions. They are calibrated with known pH levels of solutions before use to ensure the accuracy and precision of results. They are used to ensure acidic levels in various applications ranging from water treatments to laboratories.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10527

PH Meters Market: Key Trends and Drivers

Growing incidences of microbial infections coupled with technological advancements in pH meters are expected to serve as lucrative growth opportunities for this market. Moreover, the increasing number of research and testing laboratories such as soil testing, water testing, and food testing laboratories is also one of the factors, expected to boost the usage of these devices.

PH Meters Market: Restraints & Challenges

Many pH meters are soluble only in low conductivity solutions especially in distilled, deionized and ultrapure water. Continuous drift, frequent calibration and short service life will result from pH glass dissolution. The dissolving process will only accelerate at elevated temperature. There are no data available for selecting the right electrode, trial and error will provide the answer such uncertainties may hamper the market.

PH Meters Market Report Findings

https://www.globalinsightservices.com/reports/ph-meter-market/

The bench top pH meters segment is likely to hold a dominant PH Meters Market share and grow at a substantial CAGR during the forecast period.

By product type, the market is segmented into benchtop, and portable pH meters. Technological advancements such as online pH meters, calibration-free measurement systems, microprocessors for auto temperature, and pressure compensation are few of the factors that are expected to propel the market growth over the next seven years. In 2022, bench top pH meters held over xx% of the overall pH meters market owing to, its wide application in academic institutes, laboratories, industrial researchers, ease of usage, and growing demand for easy accessibility and accuracy. Portable pH meters are expected to witness a lucrative growth of over 7% during the forecast period of seven years. High mobility and small size of these meters is one of the key factors attributing to its rapid growth. Stringent regulations on water treatment plants by various EPA (Environmental Protection Agency), rising health concern among the population regarding adverse effect of quality of water and easy accessibility & availability of such instruments are among few of the factors that are expected to boost the usage of pH meters across various industries.

The manual type segment is anticipated to hold a majority of the PH Meters Market size throughout the study period.

By type, the pH meters market is segmented into digital and manual type pH meter. The manual type of pH meter segment has accounted for around USD xx million in 2022. This is owing to increasing adoption of manual pH meters as these types are mainly used in food and beverages and pharmaceutical industry to measures acidity/alkalinity of a solution. pH meters are also used to measure the acidity for preserving foods and fermentation process and it gives better operational control. Therefore, the demand for manual pH meters will boost.

The food and beverages segment is anticipated to hold a majority of the PH Meters Market size throughout the study period.

Based on end-use, the market is categorized into pharmaceutical and biotechnology companies, food and beverages, environmental testing, government and academic institutions, chemicals and petrochemicals, water, and wastewater treatment and others. Among these, the food and beverages segment are projected to witness xx% CAGR from 2022 to 2032. The demand for measuring pH meters in food and beverages industry for maintaining quality, safety, and consistency in food and beverages is increasing annually. Measuring pH value is one of the parameters measured during an inspection of the product before release. For instance, during cheeses-making, enzymatic activity is highly dependent on pH for improving yield and enhancing flavor.

Additionally, controlling pH regulates the growth of desirable and non-desirable microorganisms. Thus, to maintain different types of food such as acidified food, fermented food, and low-acid canned food, resulting in an increase in demand for pH meter thereby, driving the overall market statistics.

The North America region is estimated to exhibit the highest growth rate during the PH Meters Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Europe pH meters market is expected to grow at xx% CAGR over the forecast period. The regional growth is attributable to the technological advancement integrated within the pH meter and rising regulatory landscape in developed as well as developing countries. Further, increasing incidences of water borne diseases will spur the regional market statistics. For instance, according to the European Centre for Disease Prevention and Control (ECDC), in 2018, Europe countries reported 26 confirmed cases of cholera.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10527

Competitive Landscape

Some of the prominent industry players operating in the pH meters industry include Thermo Fisher Scientific, Contech Instruments, Emerson Electric Co. (Rosemount Analytical), Hach, Qingdao Tlead International, Hamilton Company, PCE Instruments, Hanna Instruments, Inc., Panomex Inc., Shanghai Selon Scientific Instrument Co., Ltd., Horiba, Jenco Instruments Inc., Metrohm AG, TECPEL CO., LTD., Agilent Technologies, and Mettler-Toledo International Inc., among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In March 2020, Metrohm AG launched new handheld 913 pH/DO Meter. This pH meter can measure pH value and concentration of dissolved oxygen within the same sample.
  • In 2017, Mettler Toledo, one of the leading global precision instruments manufacturer, launched Pro2Go, a smart handheld PH meter. The portable PH meter provides accurate and fast measurement, single-handed operational capabilities, and great durability.

PH Meters Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global PH Meters Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future PH Meters Market potential from 2022 to 2032 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the PH Meters Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global PH Meters Market Segmentation

By Product

  • Bench top pH Meters
  • Portable pH Metersystem

By Type

  • Digital
  • Manual

By End-use

  • Pharmaceutical and Biotechnology Companies
  • Food and Beverage
  • Environmental Testing
  • Government and Academic Institutions
  • Chemicals and Petrochemicals
  • Water and Wastewater Treatment
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Thermo Fisher Scientific
  • Contech Instruments
  • Emerson Electric Co. (Rosemount Analytical)
  • Hach
  • Qingdao Tlead International
  • Hamilton Company
  • QIAGEN
  • PCE Instruments
  • Hanna Instruments, Inc.
  • Panomex Inc

 

Read More

Biodefense Market
March, 2023

Biodefense Market to Reach US$ 40.7 Bn by 2032, driven by rising demand for better flexibility in Service Level Agreements (SLAs) and convenience in change management procedures together with cost-cutting: Global Insight Services

New York, March 2022: According to a new research study by Global Insight Services (GIS), the global Biodefense Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 40.7 Billion by 2032.

Biodefense can be defined as the activity of preparing for, responding to and countering the acts of bioterrorism. A bioterrorism attack involves the deliberate release of bacteria, viruses and other pathogens that can cause chronic illnesses to humans, animals, agriculture and the environment. Biodefense involves various medical measures that are undertaken to protect individuals against biological threats, such as administering vaccinations and medicinal drugs, along with conducting research and various public health procedures. Biodefense products are commonly effective against anthrax, smallpox, botulism, radiation/nuclear disasters and other such catastrophes..

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10528

Biodefense Market: Key Trends and Drivers

Growing investments by government will augment the overall market progression

Growing investments by government in R&D that encourages pharmaceutical and biopharmaceutical companies to boost the production of vaccines will propel the biodefense market share. Increasing global biological threats has created need for funds to support the R&D activities. Government authorities’ stock large amounts of vaccines and bio-threat detection devices to combat against the deliberate virus attacks. For instance, as per the FDA FY 2023 budget, investment of USD 1.6 billion over five years has been allocated for biodefence vaccines and development of biodefense diagnostic devices. Therefore, growing investments in biodefense enables biopharmaceutical companies to manufacture technologically advanced biothreat detection devices that will significantly drive the industry outlook.

Biodefense Market: Restraints & Challenges

KPO industry faces challenges like shortage of manpower and knowledge issues concerns for data security and poor infrastructure, and rise in real-state costs. All of these factors combined tend to be huge challenges for the industry to grow and prosper. For example, the KPO industry requires professionals with the right skill-sets and domain knowledge but there’s a shortage of such professionals especially in developing economies.

Biodefense Market Report Findings

https://www.globalinsightservices.com/reports/biodefense-market/

The anthrax segment is likely to hold a dominant Biodefense Market share and grow at a substantial CAGR during the forecast period.

By product, the biodefense market is segmented into anthrax, botulism, smallpox, radiation/nuclear, and other products. The anthrax segment held the largest market share of xx% in 2022 and is expected to grow at a significant CAGR over the forecast period. Based on products, the market is segmented into anthrax, smallpox, botulism, radiation/ nuclear, and others. Bacillus anthracis is a gram-positive bacterium that causes anthrax. It is one of the most likely to be used potential weapons for a bioterrorist attack. These spores are mostly preferred as they can be easily released into the environment by placing them in food, water, powder, and sprays.

They can last for a long time in the environment and are easily found in nature (soil, plants, or water). According to NCBI, anthrax bacteria is categorized as a tier-1 biological agent as it can be easily transmitted from one person to another and holds the potential for a major public health tragedy. Countermeasures against anthrax remain one of the key areas for countermeasures. It has received major funding for vaccine development. This includes project bioshield, which has witnessed over USD 50 billion in funding since the September 11 attack in the United States. Many companies have their vaccine for anthrax in clinical trials.

The other product segment is expected to be the fastest-growing segment with a 6.2% CAGR over the forecast period. It includes viruses like include viral hemorrhagic fever, brucellosis, cholera, influenza, plague, food poisoning, tularemia, Zika, Ebola, and many others. The National Institute of Allergy and Infectious Diseases (NIAID) has a Vaccine Research Centre (VRC), which is working on VHF vaccines since 2003, especially against Ebola and Marburg viruses. The University of Texas at San Antonio (UTSA) has been awarded a contract from the U.S. Department of Defense (DoD) to develop a vaccine against tularemia. Tularemia being highly infectious and at times fatal in nature is a potential option for a bioweapon. Recently many countries are witnessing rising infection cases due to the zika and ebola viruses and therefore many companies are competing to develop its vaccine. MVA-BN Filo, manufactured by Bavarian Nordic, is a vaccine against two filoviruses, Ebola, and Marburg’s diseases, and is currently under phase 3 clinical trials and has collaborated with the U.S. NIAID for the same.

The Asia-Pacific region is estimated to exhibit the highest growth rate during the Biodefense Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the Biodefense market capturing an xx% market share in 2022 and is expected to showcase a significant CAGR in the forecast period. This is attributed to the presence of high federal funding, technological advancements, and growing awareness among the population. The presence of major players in this region is also a favorable prospect for the biodefense market in 2022. Based on Federal Research and Development (R&D) in the fiscal year 2017, out of the total federal R&D funding that was received by eight federal agencies, 96.3% of it was received by the Department of Defense (39.3%) and the Department of Health and Human Services (27.3%) combined accounting for more than two-thirds of all federal R&D funding. This percentage of funding to DoD is proposed to increase to 48.4% in 2019. The introduction of the National Biodefense Strategy in 2018, with the purpose to detect and contain biothreats at their source. The policy also aims to support and promote biomedical innovation, and improve emergency response in case of biological outbreaks. These are some of the factors contributing to the high market growth in the region.

Asia Pacific is expected to witness the highest CAGR of 9.1% over the forecast period due to surging investments in R&D. The growing significance of biodefense, and the rising threat of harmful biological materials that engender emergencies is driving the market growth. Australia and Japan are two of the most mature Asia Pacific biodefense industry as it has well-established vaccine production facilities in the country. This coupled with the presence of sophisticated healthcare infrastructure in the country contributes to its market position. Countries like India and China are rigorously expanding their R&D capabilities to cater to biological threats in the future. China is the second country after the U.S to spend the largest percentage of its GDP on R&D. These are the factors that are expected to boost the biodefense industry in the region.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10528

Competitive Landscape

The key players in the market are XOMA corporation; Altimmune Inc. Emergent Biosolutions Inc.; Dynavax Technologies Corporation; SIGA Technologies; Elusys Therapeutics Inc.; Ichor Medical Systems; Dynport Vaccine Company; Cleveland Biolabs; Bavarian Nordic; Ology Bioservices; Alnylam Pharmaceuticals Inc. among others.

Recent Developments in the Biodefense Market:

  • June 2022: Emergent BioSolutions Inc. (NYSE:EBS) announced that the United States Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted).
  • May 2022: Emergent BioSolutions Inc. announced that it has entered into a definitive agreement with Chimerix, Inc. to acquire Chimerix’s exclusive worldwide rights to TEMBEXA (brincidofovir), the first antiviral approved by the United States Food and Drug Administration (FDA) for all age groups for the treatment of smallpox.
  • In April 2022, Heat Biologics, Inc. announced the completion of its acquisition of Elusys Therapeutics, Inc., a commercial-stage biodefense firm and developer of the anthrax therapy ANTHIM (obiltoxaximab). ANTHIM is approved for use in the United States and Canada, as well as in Europe and the United Kingdom, under the brand name Obiltoxaximab SFL.
  • in January 2022, integrated Viral Protection (IVP), a Texas-based technology business, released a new portable air filtration equipment that can eliminate airborne viruses in a single pass, including sub-micron versions producing COVID-19, anthrax spores, allergens, and other dangerous respiratory triggers.

Biodefense Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Biodefense Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Biodefense Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Biodefense Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Biodefense Market Segmentation

By Product

  • Anthrax
  • Botulism
  • Smallpox
  • Radiation/Nuclear
  • Other Products

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • XOMA corporation
  • Altimmune Inc.
  • Emergent Biosolutions Inc.
  • Dynavax Technologies Corporation.
  • SIGA Technologies.
  • Elusys Therapeutics Inc.
  • Ichor Medical Systems.
  • Dynport Vaccine Company.
  • Cleveland Biolabs.
  • Bavarian Nordic.

 

Read More

Compounding Pharmacies Market
February, 2023

Compounding Pharmacies Market to Reach US$ 20.8 bn by 2032, driven by the increase in prevalence of chronic disease, increase in old age population and improved life expectancy: Global Insight Services

New York, February 2022: According to a new research study by Global Insight Services (GIS), the global Compounding Pharmacies Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 20.8 bn by 2032.

An Compounding Pharmacies is a type of financial institution that provides loans and other forms of financing to individuals and businesses. These platforms typically use online platforms and peer-to-peer lending models to connect borrowers with lenders. Alternative lending platforms typically have lower borrowing costs and faster funding timelines than traditional banks.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10526/

Compounding Pharmacies Market: Key Trends and Drivers

Shortage of different drugs including lifesaving drugs and other cancer medicines will boost the demand from compounding pharmacies. Some of the major factors responsible for shortages are quality and manufacturing issues. Moreover, disruption of supply chains due to the COVID-19 pandemic has also resulted in delays in the process. The postponement in raw materials supply leads to a delay in manufacturing process. This ultimately affected the supply of medication leading to its shortage. Limited capability of raw material suppliers along with long lead times and complexity of manufacturing process increases drug shortages. Drug shortages can lead to delayed or cancelled patient care and can adversely affect healthcare system revenues. Additionally, shortage of lifesaving drugs along with the unavailability of alternatives could lead to death of the patient. Therefore, capability of compounding pharmacies to critically fill the crucial gap will fuel the market expansion.

Compounding Pharmacies Market: Restraints & Challenges

The key restraints and challenges in the Compounding Pharmacies market include the stringent regulations, the need for a large amount of capital, and the lack of awareness among small businesses. The stringent regulations are the primary restraint for the growth of the Compounding Pharmacies market..

Compounding Pharmacies Market Report Findings

https://www.globalinsightservices.com/reports/compounding-pharmacies-market/

The Parenteral segment is anticipated to hold a majority of the Compounding Pharmacies Market size throughout the study period.

Based on the product, the Compounding Pharmacies market is divided into Oral, Topical, Rectal, Parenteral, Opthalmic, Nasel, and Otic. Compounding pharmacies market from parenteral segment was valued at more than USD 2 billion in 2021. Factors such as rapid absorption, faster action of the drugs, control over the dose & rate of drug administration, better bioavailability, first-pass metabolism avoidance, and reliable dosage make parenteral administration the preferred option over other routes of drug administration in emergency situations, including anaphylactic shock and cardiac arrest, as it has more predictable pharmacokinetic and pharmaco-dynamic outcomes.

The Hormone Replacement segment is anticipated to hold a majority of the Compounding Pharmacies Market size throughout the study period.

Based on the therapeutic area, the Compounding Pharmacies market is divided into Nutritional Supplements, Hormone Replacement, Dermatology, Pain Management, and Specialty Drugs. Compounding Pharmacies Market from hormone replacement segment was worth more than USD 3 billion in 2021. The surging demand for regenerative medicines for reproductive cycle boosting, thyroid hormone therapy, growth hormone replacement therapy, and anti-aging therapies, such as menopause hormone replacement, is driven by their high effectiveness, comparatively safe profile, and cost efficiency, which will positively impact the overall market.

The veterinary application segment is likely to hold a dominant Compounding Pharmacies Market share and grow at a substantial CAGR during the forecast period.

By application, the industry is bifurcated into Pediatric, Geriatric, Veterinary, and Adult. Compounding pharmacies market size from the veterinary application segment valued at over USD xx billion in 2022. Veterinarians prescribe a range of drugs from antibiotics to parasite preventatives and anti-seizure medications depending on the requirements. When none of the commercially available drugs are suitable to cater to the treatment needs of the furry patient, veterinarians opt for compounded medications to meet the specific treatment requirements. Additionally, the growing presence of veterinary clinics and increased pet adoption rates globally will fuel the segment progress.

The pharmaceutical dosage alteration (PDA) segment is anticipated to hold a majority of the Compounding Pharmacies Market size throughout the study period.

Based on, the Compounding Type is categorized into Pharmaceutical Dosage Alteration [PDA], Currently Unavailable Pharmaceutical Manufacturing [CUPM], Pharmaceutical Ingredient Alteration [PIA], and Others. The pharmaceutical dosage alteration (PDA) segment held around xx% of the market share in 2022. This segment comprises of compounding of drugs with altered dosage forms specific to the patient’s need. The alteration can be made in the drug form such as solid or liquid or it can also be in the dose. The increasing need for altered medication will boost the segment expansion.

The Hospital Pharmacy segment is anticipated to hold a majority of the Compounding Pharmacies Market size throughout the study period.

Based on distribution channel, the Compounding Pharmacies market is divided into Compounding Pharmacy, Hospital Pharmacy, and Others. The hospital pharmacy segment dominated more than 52% of the compounding pharmacies market share in 2022. The market is expanding gradually, especially owing to favorable regulatory scenarios in major economies. Thus, to take the advantage of lucrative opportunities, several hospitals are entering into the market to provide compounded medications through hospital pharmacies..

The Europe region is estimated to exhibit the highest growth rate during the Compounding Pharmacies Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The Europe compounding pharmacies market is projected to exhibit a CAGR of more than xx% over the analysis timeframe. The region may emerge as a major revenue hub owing to rising awareness regarding compounded medications, shortage of certain commercially available drugs, and the need for customized individual-focused treatments. The availability of advanced infrastructure and several government initiatives toward the development of compounding pharmacies are some other factors that will favor regional market value.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10526/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Compounding Pharmacies market include Fagron, B. Braun, Nephron Pharmaceuticals Corporation, Fresenius Kabi, Athenex Pharma Solutions (Athenex Inc.), Dougherty’s Pharmacy, Inc., Clinigen Group PLC, Pencol Compounding Pharmacy, Lorraine’s Pharmacy, McGuff Company Inc. (McGuff Compounding Pharmacy Services), Institutional Pharmacy Solutions, Rx3 Compounding Pharmacy, Wedgewood Village Pharmacy, Inc., and Triangle Compounding Pharmacies. among others.

Recent Developments in the Compounding Pharmacies Market:

  • In July 2022 Fagron acquired from Fresenius Kabi a 503B outsourcing facility in Boston. Fagron expanded its United States sterile coumpounding footprint.
  • In March 2022 Fresenius Kabi acquired major stake in mAbxience which significantly enhances Fresenius Kabi’s presence in high-growth biopharmaceuticals market.

Compounding Pharmacies Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Compounding Pharmacies Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Compounding Pharmacies Market potential from 2022 to 2032 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Compounding Pharmacies Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Compounding Pharmacies Market Segmentation

By Product

  • Oral
  • Topical
  • Rectal
  • Parenteral
  • Opthalmic
  • Nasel
  • Otic

By Therapeutic Area

  • Nutritional Supplements
  • Hormone Replacement
  • Dermatology
  • Pain Management
  • Specialty Drugs
  • Others

By Application

  • Pediatric
  • Geriatric
  • Veterinary
  • Adult

By Compounding Type

  • Pharmaceutical Dosage Alteration [PDA]
  • Currently Unavailable Pharmaceutical Manufacturing [CUPM]
  • Pharmaceutical Ingredient Alteration [PIA]
  • Others

By Distribution Channel

  • Compounding Pharmacy
  • Hospital Pharmacy
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Fagron
  • B. Braun
  • Nephron Pharmaceuticals Corporation
  • Fresenius Kabi
  • Athenex Pharma Solutions (Athenex Inc.),
  • Dougherty’s Pharmacy, Inc.
  •  Clinigen Group PLC
  • Pencol Compounding Pharmacy,
  •  Lorraine’s Pharmacy
  • McGuff Company Inc

 

Read More

COVID-19 Detection Kits Market
February, 2023

COVID-19 Detection Kits Market to Reach US$ 2.2 Bn by 2032, driven by the government mandates requiring COVID-19 negative reports for various purposes, particularly air travel: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global COVID-19 Detection Kits Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 2.2 Billion by 2032.

The novel coronavirus is a single-stranded RNA coronavirus that resembles existing SARS-CoV and bat coronaviruses. As this spreads by close contact with an infected individual and is largely spread through respiratory droplets produced by coughing and sneezing. COVID-19 Detection Kit is a one-step real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in oropharyngeal and nasopharyngeal swab specimens, anterior nasal and mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates, as well as bronchoalveolar.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10525

COVID-19 Detection Kits Market: Key Trends and Drivers

The advent of new cutting-edge testing technologies to mitigate the adverse impact of the current pandemic is anticipated to foment the organic revenue growth of players engaged in supplying detection kits. For instance, a large-scale next-generation sequencing (NGS) technology exhibits the potential to run up to 100,000 pooled samples in a single instrument within 8 to 12 hours, which escalates the testing capacity. Although these technologies are still in the research phase, they provide lucrative opportunities for market progression in the forthcoming years.

COVID-19 Detection Kits Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

COVID-19 Detection Kits Market Report Findings

https://www.globalinsightservices.com/reports/covid-19-detection-kits-market/

The Immunoassay Test Strips/Cassettes segment is likely to hold a dominant COVID-19 Detection Kits Market share and grow at a substantial CAGR during the forecast period.

Based on Product, the market is bifurcated into RT-PCR Assay Kits, and Immunoassay Test Strips/Cassettes. Immunoassay test strips/ cassettes segment accounted for around xx% revenue share in 2022 and is set to register a significant CAGR through 2032. This segment is further divided into antigen test and antibody test. This is due to the rising preference towards strips/ cassettes over RT-PCR assay as they are easy to use and are rapid as well as cost-effective. These tests are used for point of care diagnosis as they show results in a couple of minutes or a few hours. Moreover, increasing new product launch and growing technological advancements in immunoassay test strips/ cassettes for virus detection will spur the market trends..

The oropharyngeal swab segment is anticipated to hold a majority of the COVID-19 Detection Kits Market size throughout the study period.

COVID-19 detection kits market based on specimen type is classified into nasopharyngeal swab, nasal swab, oropharyngeal swab, and others. The oropharyngeal swab segment surpassed USD xx billion in 2022. The swab is collected from the rear wall of the oropharynx, that is back of the throat and is inserted orally and rotated a few times for sample collection by doctors or trained professionals. This is due to the widespread availability of test swab and ease in the collection of oropharyngeal swab samples. These swabs are more comfortable and a safer method for patients who have certain critical conditions like nose bleeds or polyps. Such factors surge the demand for COVID-19 detection kits.

The hospitals segment is anticipated to hold a majority of the COVID-19 Detection Kits Market size throughout the study period.

Based on the end-use, the market is bifurcated into hospital, diagnostic laboratories and others. COVID-19 detection kits market based on end-use is classified into hospitals, diagnostic centers, and others. The hospitals segment accounted for xx% revenue share in 2022 and projected to record a lucrative CAGR in the coming years. This is driven by the increasing healthcare expenditure to provide a proper diagnosis, treatment in hospitals that increases the demand for COVID-19 detection kits. Furthermore, hospitals are well equipped with advanced medical equipment to treat patients in critical conditions and the presence of skilled professionals will further propel the industry expansion. According to the data published by the World Health Organization, in North America approximately 2,575,504 deaths were observed due to COVID-19 infection as of February 2022. Such increasing number of deaths necessitates for proper patient care in hospitals. These factors will accelerate the industry trend.

The Asia Pacific region is estimated to exhibit the highest growth rate during the COVID-19 Detection Kits Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Asia Pacific is estimated to dominate the market with a revenue share of 36.88% in 2020. This is attributed to the continuous upsurge in coronavirus cases in Asian countries such as India, a rise in the number of diagnostic facilities, and the implementation of mass testing programs in this region. As of June 2020, Wuhan, a province of China, completed the mass testing of its 11 million individuals and ended up with 206 positive asymptomatic cases of COVID-19 in Wuhan. The supportive government initiatives also surge the demand as well as usage for COVID-19 detection kits in this region. For instance, in June 2020, the Indian Council of Medical Research, India, planned to expand the utilization of rapid antigen-based coronavirus tests instead of RT-PCR tests for more rigorous COVID-19 detection. These rapid diagnostic tests are characterized by minimal biosafety hazards and thus are widely accepted by the service providers.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10525/

Competitive Landscape

The global COVID-19 Detection Kits Market report includes players are GI, Abbott Laboratories, Qiagen, Quidel Corporation, GenMark Diagnostics, Seegene, Shenzhen Bioeasy Biotechnology, BioFire Diagnostics, Guangzhou Wondfo Biotech, F. Hoffmann-La Roche, Mylab Discovery Solutions, Randox Laboratories, Cepheid, Co-Diagnostics, SD Biosensor, and Thermo Fisher Scientific among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In August 2020, Kroger Health expanded its testing portfolio by launching a COVID-19 testing program for employers- COVIDCare Plus that deploys a self-administered collection method for clinical processes. This program provides a rapid, interim testing solution, and enables the company’s in-store clinics to have a testing capability of over 5,000 patients per day.
  • In August 2020 as a cost-efficient and fast alternative to the conventional NP swabs. Major service providers including LabCorp and Quest Diagnostics are seeking to use this new swab type for an effective testing process.
  • In August 2020, PerkinElmer, Inc. entered into a public-private partnership with the California government to provide up to 150,000 new daily tests initiating from mid-November. The partnership also focuses on the lowering of the overall cost per COVID-19 test to nearly USD 47.99. This initiative is anticipated to double the capacity of COVID-19 tests and further strengthens the market presence of Perkin Elmer in the global market
  • In June 2020, the Indian Council of Medical Research, India, planned to expand the utilization of rapid antigen-based coronavirus tests instead of RT-PCR tests for more rigorous COVID-19 detection. These rapid diagnostic tests are characterized by minimal biosafety hazards and thus are widely accepted by the service providers.
  • In April 2020, Novacyt, a French diagnostic company, collaborated with GlaxoSmithKline, AstraZeneca, and the University of Cambridge to increase testing for COVID-19. Under this collaboration, a new testing laboratory would set up by GlaxoSmithKline, AstraZeneca, and the University of Cambridge at the Anne McLaren laboratory of the university. The new facility uses alternative chemical reagents for kits to overcome supply shortages in the U.K..

COVID-19 Detection Kits Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global COVID-19 Detection Kits Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future COVID-19 Detection Kits Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the COVID-19 Detection Kits Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global COVID-19 Detection Kits Market Segmentation

By Product

  • RT-PCR Assay Kits
  • Immunoassay Test Strips/Cassettes

By Specimen Type

  • Nasopharyngeal Swab
  • Oropharyngeal Swab
  • Nasal Swab
  • Others

By End-use

  • Hospital
  • Diagnostic Centers
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • BGI
  • Abbott Laboratories
  • Qiagen
  • Quidel Corporation
  • GenMark Diagnostics
  • Seegene
  • Shenzhen Bioeasy Biotechnology
  • BioFire Diagnostics
  • Guangzhou Wondfo Biotech
  • F. Hoffmann-La Roche

 

Read More

Vaccine Market
February, 2023

Vaccine Market to Reach US$ 76.9 Bn by 2032, driven by newly emerging infectious pathogenic diseases has influenced the need for effective vaccines across the globe: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Vaccine Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 76.9 Billion by 2032.

A vaccine is a biological which is used to boost the person’s immune system and help to provide immunization against chronic diseases. The suspension consists of either weakened or killed forms of disease-causing microorganisms that enhance immunity without causing diseases. The vaccine provides active immunity against a specific harmful agent such as diseases caused by a certain pathogen, injection, bacteria, virus, or parasites. By stimulating the immune system to attack the agent and eliminating these agents and increasing the life of adults and elderly individuals. After stimulation by a vaccine, B lymphocytes remain sensitized and ready to respond to the agent whenever it enters the body next time.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS20092/

Vaccine Market: Key Trends and Drivers

The expanding availability of preventive as well as therapeutic vaccines for range of diseases will boost the market expansion. Furthermore, newly emerging infectious pathogenic diseases has influenced the need for effective vaccines across the globe. This has driven the R&D activities undertaken by the operational players as well as dedicated research institutes. Advancement in vaccine development technologies to increase its efficacy and liability will offer innovative solutions to address existing disease burden. The adoption of novel development approaches including DNA/RNA vaccines, nanoparticle vaccines, and rational design will foster the vaccines market expansion.

Vaccine Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Vaccine Market Report Findings

https://www.globalinsightservices.com/reports/vaccines-market/

The adult segment is likely to hold a dominant Vaccine Market share and grow at a substantial CAGR during the forecast period.

Based on age group, the market is bifurcated into S Pediatric, and Adult. Adult vaccines segment is projected to proceed at xx% CAGR during the forecast timeframe. This is attributable to increased COVID-19 vaccination rate among adults. Moreover, the awareness and improving accessibility of various preventive vaccines that helps to reduce the risk of severe infections in adults will drive the segment revenue. Additionally, some countries have established the vaccination policies and regulations for adults while travelling to particular nations to avoid the risk of disease transmission, that has further influenced the vaccination rate in adults.

The Inactivated segment is anticipated to hold a majority of the Vaccine Market size throughout the study period.

Based on the technology, the market is bifurcated into Conjugate, Live, Inactivated, Recombinant, Toxoid. Vaccines market from inactivated segment exceeded USD xx billion in 2022. This is attributed to the ability of inactivated vaccines in destruction of pathogen replication. This offers effective protection against various dreadful pathogenic diseases such as hepatitis A, influenza, polio, and rabies. Moreover, these vaccines prevent the reversal activity of pathogens to more pathogenic phenotype and avoids the interference with other functional molecules during the combination therapies. This leads to preference for inactivated technology over the live vaccines. Furthermore, as it can stored without refrigeration for certain period as the pathogen is dead, it offers ease in transportation and storage that will continue to increase its demand.

The Hepatitis segment is anticipated to hold a majority of the Vaccine Market size throughout the study period.

Based on the application, the market is bifurcated into Cancer, Hepatitis, Pneumococcal Disease, Influenza, Rotavirus, COVID-19, and others. The higher recommendation of HPV vaccination for preteens, teens as well as younger adults as it can lead to different types of cancer will enhance the industry landscape. For instance, as per the Centers for Disease Control and Prevention, each year, nearly 14 million Americans, including teens are anticipated to be infected with HPV. The vaccination also prevents the risk of cervical cancer development in women. Thus, increasing vaccination rate across the developed and developing regions to reduce further risk of severe diseases associated with HPV will stimulate the market statistics.

The Europe region is estimated to exhibit the highest growth rate during the Vaccine Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Europe vaccines market accounted for xx% revenue share in 2022. This is attributable to the adoption of new technologies and expanding awareness about the preventive vaccines in the region. The government organizations are implementing some strategies to broaden accessibility for the emerging infectious disease treatments including the COVID-19. In addition, the industry players entered in collaboration with non-government organizations to provide COVID-19 vaccines considering significantly increasing disease incidence in the region.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS20092/

Competitive Landscape

The global Vaccine Market report includes players are AstraZeneca plc., CSL Limited, Emergent BioSolutions Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Novavax, Pfizer Inc, Sanofi S.A., and Serum Institute of India, among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In February 2021, Ceva partnered with the French National Research Institute for Agriculture, Food, and Environment (INRAE) for R&D in the prevention of infectious diseases from animal origin and improvement of animal health.
  • In January 2021, Zoetis launched the Poulvac Procerta HVT-IBD vaccine for the protection of poultry against Infectious Bursal Disease (IBD). This added to the company line of recombinant vector vaccines.
  • UNICEF and Pfizer entered into a supply agreement for the COVID-19 vaccines distribution throughout 2021. This has helped the company to maintain broaden its distribution across the globe, thereby driving the business revenue.

Vaccine Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Vaccine Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Vaccine Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Vaccine Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Vaccine Market Segmentation

By Age Group

  • Pediatric
  • Adult

By Technology

  • Conjugated
  • Live
  • Inactivated
  • Recombinant
  • Toxoid
  • Others

By Application

  • Cancer
  • Hepatitis
  • Pneumococcal Disease
  • Influenza
  • COVID-19
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • AstraZeneca plc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Merck & Co.
  • Novavax
  • Pfizer Inc
  • Sanofi S.A.
  • Serum Institute of India

 

Read More

Outpatient Oncology Infusion Market
February, 2023

Outpatient Oncology Infusion Market to Reach US$ 205.3 bn by 2032, driven by Rising prevalence of cancer along with the growing demand for outpatient infusion therapy for cancer treatment: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Outpatient Oncology Infusion Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 205.3 bn by 2032.

The outpatient oncology infusion centers offer a variety of treatments such as chemotherapy, blood transfusions, platelet transfusions, IV antibiotics, and hydration and electrolyte replacement. It also provides long-term and short infusion therapy to patients in an appropriate manner.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10523/

Outpatient Oncology Infusion Market: Key Trends and Drivers

The market is acquiring significant importance due to increasing technological advancements in infusion pumps. Additionally, the growing demand for outpatient infusion therapy for cancer treatment is anticipated to boost the market expansion. Rise in advanced technology has allowed infusion pumps to exhibit electronic health record integration such as built-in infusion and drug library of list of drugs stored in smart pump’s memory. Such advancement helps to prevent medication errors. Further, this advancement has enabled infusion system to connect to the electronic medical record by interoperability software. This provides the ability to communicate and share data accurately, effectively, and securely with different devices.

Outpatient Oncology Infusion Market: Restraints & Challenges

The key restraints and challenges in the Outpatient Oncology Infusion market include the stringent regulations, the need for a large amount of capital, high cost of treatment, and the lack of awareness among individuals regarding advanced treatment.

Outpatient Oncology Infusion Market Report Findings

https://www.globalinsightservices.com/reports/outpatient-oncology-infusion-market/

The intravenous sets segment is anticipated to hold a majority of the Outpatient Oncology Infusion Market size throughout the study period.

Based on the product, the Outpatient Oncology Infusion market is divided into Infusion Pumps, Intravenous Sets, IV Cannulas, and Needleless Connectors. Intravenous sets segment accounted for xx% revenue share in 2022 and is set to register a significant CAGR through 2032. Intravenous sets are a flexible tube that helps in smooth medication. These sets are mostly used to deliver photosensitive fluids to oncology patients and protect from light during distribution. Also, it delivers light-sensitive APIs and pharmaceutical products. Such benefits associated with this product will accelerate the industry trends.

The lung cancer segment is anticipated to hold a majority of the Outpatient Oncology Infusion Market size throughout the study period.

By application, the industry is bifurcated into Lung Cancer, Liver Cancer, Breast Cancer, and Prostate Cancer. Prostate cancer segment exceeded USD xx billion in 2022. This is owing to growing awareness among individuals regarding the prostate cancer therapy along with rising prevalence of prostate cancer. Moreover, increasing adoption of innovative infusion pump in cancer diagnosis coupled with development of targeted and immunotherapies therapies for the treatment of prostate cancer is projected to drive the business landscape.

The targeted therapy segment is likely to hold a dominant Outpatient Oncology Infusion Market share and grow at a substantial CAGR during the forecast period.

Based on therapy, the industry is categorized into Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy. Outpatient oncology infusion market from targeted therapy segment accounted for around xx% business share in 2022 and projected to record a lucrative CAGR in the coming years. Targeted therapies are utilized to specifically target cancer cells while causing no harm to the body’s normal cells. It is frequently combined with additional treatments like regular or traditional chemotherapy, radiation therapy, or staging operations. The targeted treatments aid in the treatment of cancer including multiple myeloma, prostate cancer, melanoma, lymphoma, and breast cancer. This is done by interfering with specific protein types that aid tumor development and circulation. The rate of cancer development in the body can be considerably lowered using this method.

The intramuscular (IM) segment is anticipated to hold a majority of the Outpatient Oncology Infusion Market size throughout the study period.

Based on mode, the Outpatient Oncology Infusion market is divided into Intramuscular (IM), Intravenous (IV), and Subcutaneous. The intramuscular (IM) segment is projected to witness xx% CAGR from 2022 to 2032. The intramuscular method is used to administer the majority of vaccinations. Such a method of administration lowers adverse effects at the injection site. Intramuscular injections are useful because they deliver drugs deep into muscle tissue, resulting in rapid absorption into the bloodstream.

The Asia-Pacific region is estimated to exhibit the highest growth rate during the Outpatient Oncology Infusion Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Asia Pacific outpatient oncology infusion market exceeded USD xx billion in 2022. This is primarily due to the improving outpatient healthcare facilities coupled with rising geriatric population. Such factors encourage the market players to develop innovative infusion devices to increase their quality of life. Additionally, several government initiatives are creating opportunities for market players to introduce novel infusion devices. Hence, such favorable factors are anticipated to upsurge the need for outpatient oncology infusion therapy to maintain the good health of patients, thereby fueling the regional market progression.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10523/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Outpatient Oncology Infusion market include B. Braun Melsungen AG, Baxter, Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc., IRadimed Corporation, Nipro Corporation, Terumo Corporation, Smiths Medical, Medtronic PLC, Roche Diagnostics, and Teleflex, Inc. among others.

Recent Developments in the Outpatient Oncology Infusion Market:

  • In December 2021, B. Braun Medical launched the next generation OnGuard 2 CSTD. This device prevents the release of chemotherapy drug vapors and aerosols under extreme conditions. Such a product launch helped the company to enhance its product portfolio and its market position.
  • In May 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS™ (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
  • In September 2018, Pfizer received U.S. FDA approval for VIZIMPRO for the first line treatment for patient with EGFR-mutate metastatic non-small cell lung cancer.

Outpatient Oncology Infusion Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Outpatient Oncology Infusion Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Outpatient Oncology Infusion Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Outpatient Oncology Infusion Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Outpatient Oncology Infusion Market Segmentation

By Product

  • Infusion Pumps
  • Intravenous Sets
  • IV Cannulas
  • Needleless Connectors

By Application

  • Lung Cancer
  • Liver Cancer
  • Breast Cancer
  • Prostate Cancer

By Threapy

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy

By Mode

  • Intramuscular (IM)
  • Intravenous (IV)
  • Subcutaneous

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • B. Braun Melsungen AG
  • Baxter
  • Becton, Dickinson, and Company
  • Fresenius Kabi
  • ICU Medical, Inc
  • IRadimed Corporation
  • Nipro Corporation
  • Terumo Corporation
  • Smiths Medical
  • Medtronic PLC
Read More

Neurological Biomarkers Market
February, 2023

Neurological Biomarkers Market to Reach US$ 14.0 Bn by 2032, driven by the rise in the prevalence of neurological diseases, such as migraines, dementia, Alzheimer’s disease, brain tumors, and epilepsy: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Neurological Biomarkers market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 14.0 Billion by 2032.

Neurological Biomarkers is used to protect against the intentional interference of electronic signals. This equipment can be used to protect against radio frequency interference (RFI), electromagnetic interference (EMI), or other types of signal interference. There are a variety of anti-jamming technologies that can be used, depending on the type of interference that is being protected against. For example, RFI jamming can be countered with frequency-hopping spread spectrum (FHSS) technology, while EMI jamming can be countered with pulse-code modulation (PCM) or other digital modulation techniques.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10522/

Neurological Biomarkers Market: Key Trends and Drivers

Recent advancements in biomarkers, such as biomarker signatures are making neurological diseases more treatable. This has resulted in noninvasive testing, faster drug development, and early diagnosis. Furthermore, digital biomarkers provide various pharmaceutical companies with contextual and supplemental information to conclude clinical trial decisions. National Institute of Neurological Disorders and Stroke provides funding, such as development grants & cooperative agreements, for researchers conducting studies related to biomarker discovery, analytical validation, & clinical validation.

Neurological Biomarkers Market: Restraints & Challenges

The high cost of Neurological Biomarkers systems is likely to impede the market growth over the forecast period. However, the increment is not significant in the women population. Thus, such increase in Parkinsons disease in men aged 70 years and over is projected to supplement the market growth owing to the increase in demand for biomarkers for diagnosis.

Neurological Biomarkers Market Report Findings

https://www.globalinsightservices.com/reports/neurological-biomarker-market/

The proteomic segment is likely to hold a dominant Neurological Biomarkers market share and grow at a substantial CAGR during the forecast period.

On the basis of type, it is segmented into genomic, proteomic, metabolomic, imaging, and others. The proteomic segment accounted for the highest revenue share of over xx% in 2022. Genomic biomarkers accounted for the second-largest market share in 2022. Genomic biomarkers present promising opportunities for the development of personalized medicines and diagnostics based on an individual’s specific genetic variations & predisposition to the disease. The methods used for detecting the presence or studying genomic biomarkers for the identification of disease-associated DNA sequence variants include array Comparative Genomic Hybridization (CGH), gene expression profiling, whole-genome association studies using Single Nucleotide Polymorphisms (SNPs), and whole-genome resequencing.

The others segment is anticipated to witness significant CAGR over the forecast period due to the increasing adoption of digital biomarkers in clinical trials patient selection for neurological drugs. For instance, IXICO plc – a digital technology-based company, with expertise in neurosciences-is collaborating with biopharmaceutical companies to validate clinically digital biomarkers and use them in clinical trials.

The alzheimer disease segment is anticipated to hold a majority of the Neurological Biomarkers market size throughout the study period.

By application, the industry is classified into alzheimer disease, parkinson disease, multiple sclerosis, autism spectrum disorder, and others. The Alzheimer disease application segment accounted for the largest market share of over xx% in 2022 and is expected to remain dominant during the forecast period. This growth is credited to the high disease burden and availability of products for clinical use, such as imaging biomarkers-amyloid PET tracers for diagnosis. Furthermore, the government and non-profit organizations are providing a plethora of research opportunities that may fuel market growth. The Alzheimer Association in collaboration with The Michael J. Fox Foundation for Parkinson Research (MJFF), Alzheimer Research U.K., and the Weston Brain Institute, introduced Biomarkers Across Neurodegenerative Diseases (BAND) that provide research funding for biomarker discovery.

The Parkinson disease application segment is expected to grow at a CAGR of xx% during the forecast period owing to the growing prevalence of the disease and an increasing number of clinical trials for the disease drugs. According to the Parkinson Foundation, around 60,000 people are diagnosed with Parkinson’s disease each year in the U.S. and over 930,000 people were suffering from the disease in 2020. Several ground-breaking research trials are being conducted for improved diagnostics of Parkinson disease. Earlier, protein biomarkers, amino acids, and dopamine metabolites were the prime analytical tools for diagnosing the disease. However, several novel candidates are under investigation for potential diagnostic biomarker.

The Hospital segment is anticipated to hold a majority of the Neurological Biomarkers market size throughout the study period.

By end-use, neurological biomarkers market has been segmented into hospital & hospital laboratories, independent clinical diagnostic centers, research organizations and others. The hospital & hospital laboratories segment accounted for the largest market share of over xx% in 2022. The segment is expected to remain dominant even during the forecast period due to a rise in hospitalization. Furthermore, the ongoing development of healthcare infrastructure is anticipated to enhance the existing hospital facilities. Most of the blood-based biomarker assays are purchased by hospitals and are used in significant volumes. The research organizations & others segment is expected to grow at the fastest CAGR xx% over the forecast years owing to the increased adoption of biomarkers by pharmaceutical companies and Ambulatory Surgery Centers (ASCs) for drug discovery & development.

The North America region is estimated to exhibit the highest growth rate during the Neurological Biomarkers market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the highest market share of over xx% in 2022 and is expected to witness a significant growth rate over the forecast period. The significantly high disease burden, acceptance of biomarkers for diagnostic, drug development & prognostic purposes, and increase in research funding are some key factors contributing to the dominance of the region. Moreover, the increasing product launches along with the rise in demand for biomarkers are expected to have a positive impact on the regional market. Asia Pacific is expected to grow at the fastest CAGR of xx% from 2022 to 2032. An increasing number of clinical trials being conducted in developing countries, such as India and China, rising disease burden, and growing need for targeted drugs in the central nervous system are factors expected to drive the regional market growth.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10522/

Competitive Landscape

The key players in the Beckman Coulter Inc. (Danaher Corporation), Biolog Inc.,, BioMerieux SA,, Bruker Corporation, Charles River Laboratories International Inc,, Eurofins Scientific SE, Liofilchem S.r.l, Merck KGaA, Shimadzu Corporation, Thermo Fisher Scientific Inc., VWR International LLC., Wickham Micro Limited, among others.

Recent Developments in the Neurological Biomarkers Market:

  • In May 2020, PerkinElmer launched of new products based on the HTRF technology. The product application includes biomarkers assays, biochemical cytokine-receptor binding assays, and other applications.
  • In March 2020, Thermo Fisher Scientific initiated the procedure for the acquisition of QIAGEN N.V. as a part of the business strategy. This transaction values QIAGEN at about US$ 11.5 billion as per the current exchange rates. It includes the consideration of about US$ 1.4 billion of net debt.
  • In December 2019, Quest Diagnostics Incorporated acquired specific assets of Boston Clinical Laboratories related to clinical laboratory services business. Boston Clinical Laboratories is a Waltham-based regional provider of laboratory services.
  • In July 2019, Quest Diagnostics Incorporated entered into a partnership with Catholic Health Services (CHS). CHS is an integrated health care delivery system that accounts for about a 24% market share on Long Island. Through this partnership, the company will be able to provide laboratory and supply chain expertise, other testing-related services.
  • In April 2019, PerkinElmer Inc. acquired Cisbio Bioassays. Cisbio Bioassays has developed its proprietary HTRF technology, a TR-FRET assay platform that has application in Life Sciences. The extension of Cisbio has enabled life science researchers to have access to assay tools for various target types and biological configurations, small molecule, and biologic drug discovery procedures.

Neurological Biomarkers Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Neurological Biomarkers market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Neurological Biomarkers market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Neurological Biomarkers market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Neurological Biomarkers Market Segmentation

By Type

  • Genomic
  • Proteomic
  • Metabolomic
  • Imaging
  • Others

By Application

  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Autism Spectrum Disorder
  • Others

By End-user

  • Hospital & Hospital Laboratories
  • Independent Clinical Diagnostic Centers
  • Research Organizations
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Banyan Biomarkers, Inc.
  • Myriad Genetics, Inc.
  • DiaGenic ASA
  • Quanterix

 

Read More

Microbial Identification Market
February, 2023

Microbial Identification Market to Reach US$ 14.0 Bn by 2032, driven by the increase in the number of military attacks in the province: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Microbial Identification market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 14.0 Billion by 2032.

Microbial Identification is used to protect against the intentional interference of electronic signals. This equipment can be used to protect against radio frequency interference (RFI), electromagnetic interference (EMI), or other types of signal interference. There are a variety of anti-jamming technologies that can be used, depending on the type of interference that is being protected against. For example, RFI jamming can be countered with frequency-hopping spread spectrum (FHSS) technology, while EMI jamming can be countered with pulse-code modulation (PCM) or other digital modulation techniques.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10521/

Microbial Identification Market: Key Trends and Drivers

The rising prevalence of infectious diseases caused by microorganisms is increasing the need for microbial identification tests across the globe. The classification of microorganisms and microbes plays a vital role in disease analysis and providing appropriate treatment. In addition, the study of bacteria, parasites, fungi, and microbes is encouraging investors in the pharmaceutical industry to finance innovation in drug development. This represents another factor positively influencing the market. Apart from this, the increasing food safety concerns around the world are driving the need for microbial identification techniques to identify food spoilage contaminants. These techniques help retain the authenticity and flavor of processed food products and increase their shelf life. Furthermore, continuous advancements in the field of microbiology and microbial identification equipment are creating a positive market outlook. Moreover, various initiatives undertaken by governments of various countries to prevent the spread of infectious diseases, coupled with the increasing expenditure on the healthcare industry, are anticipated to propel the market growth.

Microbial Identification Market: Restraints & Challenges

However, the high cost of automated microbial identification systems is likely to impede the market growth over the forecast period. Also, the high cost of automated microbial identification systems is likely to impede the market growth over the forecast period.

Microbial Identification Market Report Findings

https://www.globalinsightservices.com/reports/microbial-identification-market/

The Instruments segment is likely to hold a dominant Microbial Identification market share and grow at a substantial CAGR during the forecast period.

On the basis of Product & Service, it is segmented into Instruments, Consumables, and Services. The instruments segments are also reported to show a constant growth rate over the forecast period owing to the rising awareness among the general population about healthcare and the increasing rate of surgical procedures. For instance, in September 2019, Guthrie, a U.S.-based integrated health care system, deployed Wolters Kluwer’s POC Advisor for the detection and treatment of sepsis at four area hospitals.

The Phenotypic Methods segment is anticipated to hold a majority of the Microbial Identification market size throughout the study period.

By Method, the industry is classified into Phenotypic Methods, Genotypic Methods, Proteomics-based Methods. Among these Phenotypic Methods segment accounted for USD xx Million in 2021. Phenotypic Methods of Classifying and Identifying Microorganisms. Classification seeks to describe the diversity of bacterial species by naming and grouping organisms based on similarities. Phenotypic methods offer an advantage over genotypic methods in that they can identify a wide range of taxa, detect the resistance currently expressed, and resist genetic variability in resistance detection. Conventional phenotypic identification may involve a number of methods, including observation of growth and colony morphology on various media, analysis of manual biochemical reactions, and the use of automated and nonautomated commercially available biochemical panels.

The food and beverage testing segment is anticipated to hold a majority of the Microbial Identification market size throughout the study period.

By application, microbial identification market has been segmented into diagnostics, food and beverage testing, pharmaceuticals, cosmetics and personal care products testing, others. During the forecast period, the food and beverage testing segment is expected to grow at the fastest CAGR of xx% in the Microbial Identification Market. Accurate microbiological testing technology is vital for the detection of foodborne pathogens, possible food spoilage organisms and technological strains. Rapid identification/confirmation and strain typing methods enable food and beverage manufacturers to make fast quality and safety decisions.

The North America region is estimated to exhibit the highest growth rate during the Microbial Identification market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to dominate the microbial identification market over the forecast period owing to the factors such as the rising burden of infectious diseases and outbreaks of epidemics, growing healthcare expenditure, and the presence of well-established healthcare infrastructure. The increasing prevalence of infectious diseases in the region is the key factor fuelling the market growth. For instance, As per the data published by the Centers for Medicare & Medicaid Services, in March 2022, titled “CMS Office of the Actuary Releases 2021-2030 Projections of National Health Expenditures”, it has been observed that the annual growth in national health spending is expected to be average 5.1% over 2021-2030. Also, the National Health Spending in 2020 was USD 4.1 trillion and it is projected to reach USD 6.8 trillion by 2030. Thus, the increasing healthcare spending is expected to increase company activities and government initiatives in developing technologically advanced testing products and equipment, thereby propelling the market growth..

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10521/

Competitive Landscape

The key players in the Beckman Coulter Inc. (Danaher Corporation), Biolog Inc.,, BioMerieux SA,, Bruker Corporation, Charles River Laboratories International Inc,, Eurofins Scientific SE, Liofilchem S.r.l, Merck KGaA, Shimadzu Corporation, Thermo Fisher Scientific Inc., VWR International LLC., Wickham Micro Limited, among others.

Recent Developments in the Microbial Identification Market:

  • In November 2021, Collins Aerospace acquired FlightAware, a digital aviation company that operates flight tracking and data platforms. Moreover, in October 2020, the company was selected to provide anti-jam technology for manned and unmanned ground vehicles to combat.
  • In October 2021, Septentrio NV partnered with ArduSimple. The company integrated its modules into evaluation kits developed by ArduSimple. These new partnerships bring triple-band RTK as a plug-and-play solution for the most popular development platforms like Arduino, STM Nucleo, Raspberry Pi, Ardupilot, and Nvidia Jetson.

Microbial Identification Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Microbial Identification market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Microbial Identification market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Microbial Identification market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Microbial Identification Market Segmentation

By Technology

  • Instruments
  • Consumables
  • Services

By Application

  • Phenotypic Methods
  • Genotypic Methods
  • Proteomics-based Methods

By End-user

  • Diagnostics
  • Food and Beverage Testing
  • Pharmaceuticals
  • Cosmetics and Personal Care Products Testing
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Beckman Coulter Inc. (Danaher Corporation)
  • Biolog Inc.,
  • BioMerieux SA,
  • Bruker Corporation
  • Charles River Laboratories International Inc.
  • Eurofins Scientific SE
  • Liofilchem S.r.l
  • Merck KGaA
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.
  • VWR International LLC.
  • Wickham Micro Limited.
Read More

NGS-based RNA Sequencing Market
February, 2023

NGS-based RNA Sequencing Market to Reach US$ 21.3 Bn by 2032, driven by the advancements of in sequencing technology, increase in acceptance of NGS technology, and growth in number of partnerships & collaborations: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global NGS-based RNA Sequencing market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 21.3 Billion by 2032.

NGS-based RNA Sequencing is used to protect against the intentional interference of electronic signals. This equipment can be used to protect against radio frequency interference (RFI), electromagnetic interference (EMI), or other types of signal interference. There are a variety of anti-jamming technologies that can be used, depending on the type of interference that is being protected against. For example, RFI jamming can be countered with frequency-hopping spread spectrum (FHSS) technology, while EMI jamming can be countered with pulse-code modulation (PCM) or other digital modulation techniques.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10519

NGS-based RNA Sequencing Market: Key Trends and Drivers

Advantages offered by NGS-based RNA sequencing such as it provides a sensitive, and accurate assay of gene expressions which is increasingly the method of choice for scientists researching on the transcriptome. Moreover, RNA sequencing based on NGS captures both known and novel features. Also, it can generate both qualitative and quantitative data, saving the research time. The market is anticipated to be driven by significant factors, including an increase in cancer incidence, government research grants, and molecular biology technical developments. Moreover, contrarily, large-scale whole-genome sequencing (WGS), one of the most preferred methods in agriculture, forensics, and biofuels, is now affordable and manageable for a typical researcher by next-generation sequencing (NGS). It enables researchers to sequence thousands of genomes in a single year or to study the whole human genome in a single sequencing session.

Technological advancements in next-generation Sequencing (NGS) by top players are another factor increasing the growth of the global NGS-based RNA sequencing market. Illumina introduced its iSeq 100 System, a semiconductor sequencing technology. Sequencing by synthesis (SBS) chemistry is combined with a semiconductor chip in semiconductor sequencing technology.

NGS-based RNA Sequencing Market: Restraints & Challenges

Restraining factors for NGS in clinical microbiology include unexplained antibiotic resistance, the inability to determine which organism is causing sickness, costs, and questionable clinical utility. The high cost of sequencing is a major barrier to the adoption of NGS. The technology is still relatively new and the costs have not yet come down to a level that is affordable for many laboratories. In addition, the lack of standardization in NGS protocols means that there is no agreed upon set of best practices for data collection and analysis. This lack of standardization makes it difficult to compare results from different laboratories and makes it difficult to reproduce results. The need for skilled personnel is another challenge facing the NGS market. The technology is complex and requires a high level of technical expertise to operate. In addition, the data generated by NGS experiments can be very large and complex, making it difficult to analyze and interpret without the help of bioinformatics experts.

NGS-based RNA Sequencing Market Report Findings

https://www.globalinsightservices.com/reports/ngs-based-rna-sequencing-market/

The platforms and consumables segment is likely to hold a dominant NGS-based RNA Sequencing market share and grow at a substantial CAGR during the forecast period.

The global NGS-based RNA sequencing market based on products & services is grouped into sample preparation, platforms & consumables, services, and data analysis. In 2021, the platforms and consumables segment held the greatest market share. This expansion is due to the ongoing technological advancements in the biotech industry. The rapidly expanding availability of innovative and affordable RNA sequencing systems, including library preparation, accelerates the segment growth. In addition, the services segment is predicted to expand at a high CAGR over the projection period due to the increasing use of services like RNA isolation, library preparation, sequencing, and data analysis as part of the full sample-to-insight solutions.

The sequencing by synthesis (SBS) segment is anticipated to hold a majority of the NGS-based RNA Sequencing market size throughout the study period.

Based on technology, the global NGS-based RNA sequencing market is grouped into sequencing by synthesis, ion semiconductor sequencing, nanopore sequencing, and single-molecule real-time sequencing. The sequencing by synthesis (SBS) segment holds most of the market share. Sequencing by synthesis (SBS) is one of the widely used technology. Moreover, SBS provides robust performance and data quality; it provides unbiased coverage across the genome. Also SBS chemistry produces extremely precise sequencing using a single base extension and competitive nucleotide addition. Many top players, such as Illumina Inc. use the sequencing by synthesis (SBS) technique in their NGS systems, making it more affordable.

The De novo sequencing segment is anticipated to hold a majority of the NGS-based RNA Sequencing market size throughout the study period.

The global NGS-based RNA sequencing market is segmented on application into De novo, epigenetics, and small RNA. De novo sequencing is the process of sequencing a novel genome in the absence of an alignment table reference sequence. De novo assembly of RNA-seq data enables the study of the transcriptome, whether data are collected from a single organism or from a mixed sample, as in meta-transcriptomics investigations. NGS-based RNA sequencing in De Novo also helps clarify similar or repetitive regions for accurate de novo assembly. De novo also provides accurate data for the genome mapping of novel organisms.

The North america region is estimated to exhibit the highest growth rate during the NGS-based RNA Sequencing market forecast period.

Regionally, the global NGS-based RNA Sequencing Market has been segmented into North America, Europe, Asia Pacific, and the Rest Of The World. North America holds the leading position. The demand for early diagnosis of diseases like cancer in the region has increased as a result of the development of next-generation sequencing, which has decreased the cost of genome sequencing, a crucial stage in a gene expression study. The presence of major companies like Illumina, Thermo Fisher Scientific, and PerkinElmer and the increased focus on genome mapping projects have significantly benefited the growth of the next-generation sequencing industry in North America. According to estimates by The National Institutes of Health’s (NIH) Human Genome Research Institute (NHGRI) in March 2022, the organization supports genomic research with such generous funding. According to statistics, the United States has invested more than any other nation in genomics research over the past ten years, amounting to 35% of all public funding received globally.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10519

Competitive Landscape

The key players in the NGS-based RNA Sequencing market are Agilent Technologies, Inc., BGI Group, Eurofins Scientific SE, Genewiz, Inc. , F. Hoffman- La Roche AG, Thermo Fisher Scientific, Zymo Research Corporation, Psomagen, Inc., Hamilton Company, Qiagen N.V. among others.

Recent Developments in the NGS-based RNA Sequencing Market:

  • In December 2021, Roche launched the AVENIO Edge System to advance next-generation sequencing (NGS) technologies.
  • In February 2021, Stanford Medicine launched an in-house service for whole-genome sequencing. Similarly, Cerba Research announced two COVID-19 exploratory tools in January 2021, one PCR-based and the other NGS-based, to enhance research for vaccine development against infectious diseases, including COVID-19
  • In January 2021, Illumina and Myriad Genetics partnered to develop a kit-based version of the myChoice companion diagnostic (CDx) test. To improve the genomic profiles of tumor samples, this method integrates NGS technology with companion diagnostics.

NGS-based RNA Sequencing Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global NGS-based RNA Sequencing market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future NGS-based RNA Sequencing market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the NGS-based RNA Sequencing market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global NGS-based RNA Sequencing Market Segmentation

By Product & Services

  • Sample Preparation
  • Platforms & Consumables
  • Services
  • Data Analysis

By Technology

  • Single-Molecule Real-Time Sequencing
  • Ion Semiconductor Sequencing
  • Sequencing By Synthesis
  • Nanopore Sequencing

By Application

  •  De novo
  • Epigenetics
  • Small RNA

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Agilent Technologies Inc.
  • Illumina inc.
  • BGI Group
  • Eurofins Scientific SE
  • Genewiz, Inc.
  • F. Hoffman- La Roche AG
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corporation
  • Psomagen Inc.
  • Hamilton Company, Qiagen N.V.

 

Read More

Next-generation Sequencing Market
February, 2023

Next-generation Sequencing Market to Reach US$ 18.7 bn by 2032, driven by extensive adoption of NGS technologies in clinical diagnostics due to rapid result time and faster processing: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Next-generation Sequencing Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 18.7 bn by 2032.

Next-generation sequencing (NGS) is a type of DNA sequencing technology that is used to determine the precise order of nucleotides in a genome. NGS is also used to identify mutations, SNPs, and other variations in a genome. NGS technology has revolutionized the field of genomics by providing a more rapid and cost-effective method for sequencing genomes. NGS can sequence an entire human genome in a matter of days, whereas it would take months or years to sequence a genome using traditional methods.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10518

Next-generation Sequencing Market: Key Trends and Drivers

Growing technological developments in NGS instruments and technologies are further likely to offer significant market growth over the coming years. For instance, in January 2020, the Intelligence Advanced Research Projects Activity in the U.S. awarded a grant of USD 23 million to the Harvard University, DNA Script, and Broad Institute. The institutes are conducting collaborative research to develop a novel technology that will combine enzymatic DNA synthesis and NGS into a single instrument. To better understand the link between genetics and disease, several countries have invested in their own national population genome mapping projects. Furthermore, millions of genomes are being sequenced by government groups to progress research and discover better ways to identify and cure cancer, uncommon disorders, and other ailments. Efforts are being undertaken by the EU to improve the region large-scale genomic data with projects such as France’s French Plan for Genomic Medicine 2025 and the U.K. 100,000 Genomes Project. Such initiatives have resulted in the growth of NGS informatics services in the region.

Next-generation Sequencing Market: Restraints & Challenges

The high cost of sequencing is a major barrier to the adoption of NGS. The technology is still relatively new and the costs have not yet come down to a level that is affordable for many laboratories. In addition, the lack of standardization in NGS protocols means that there is no agreed upon set of best practices for data collection and analysis. This lack of standardization makes it difficult to compare results from different laboratories and makes it difficult to reproduce results.

The need for skilled personnel is another challenge facing the NGS market. The technology is complex and requires a high level of technical expertise to operate. In addition, the data generated by NGS experiments can be very large and complex, making it difficult to analyze and interpret without the help of bioinformatics experts.

Next-generation Sequencing Market Report Findings

https://www.globalinsightservices.com/reports/next-generation-sequencing-market/

The sequencing segment is anticipated to hold a majority of the Next-generation Sequencing Market size throughout the study period.

Based on the workflow, the Next-generation Sequencing market is divided into Pre-sequencing, Sequencing, and NGS Data Analysis. Of these, the sequencing segment held the highest market share of xx% in 2022. NGS sequencing is the most important phase of the workflow and consequently accounts for the largest share of the market. These systems can provide an accurate amount of liquid, which is important in NGS. Moreover, functions such as changing tubes and microtiter plates are also carried out by the system, which helps streamline workflow. The advantage of using a robotic liquid handling system is that it enables researchers to focus on analyzing the data rather than managing the process. For instance, Illumina’s BaseSpace Suite aids in the analysis of sequencing data and the production of findings in a short amount of time. To expand its data analytic capabilities, the company has also purchased DRAGEN Bio-IT Platform (DRAGEN) and Edico Genome. Furthermore, Genomatix and DNAnexus, provide cloud-based solutions for the interpretation and management of enormous volumes of sequencing data.

The targeted sequencing segment is anticipated to hold a majority of the Next-generation Sequencing Market size throughout the study period.

By technology, the industry is bifurcated into whole genome sequencing, whole exome sequencing, and targeted sequencing & resequencing. The targeted sequencing and resequencing segment held the highest market share of xx% in 2022. This segment is expected to witness growth in demand after the growth of whole genome sequencing, as the availability of a large amount of whole genome data will be required to be analyzed at specific gene locations and isolated genetic expressions. There are many companies in the NGS market offering targeted sequencing services. Thus, this segment is expected to grow in tandem with the WGS segment throughout the forecast period. Illumina offers targeted resequencing with its gene panel and array finder, whereas Pacific Biosciences of California’s Sequel System with its SMRT technique allows targeted sequencing and accurate detection of variants. Targeted sequencing panels are expected to remain the workhorse for cancer molecular diagnostics and are projected to become the routine part of the heme malignancies and solid tumors.

The oncology segment is likely to hold a dominant Next-generation Sequencing Market share and grow at a substantial CAGR during the forecast period.

Based on application, the industry is categorized into oncology, clinical investigation, reproductive health, hla typing/immune system monitoring, metagenomics, epidemiology & drug development, and others. The oncology segment dominated the market and accounted for the highest market share of xx% in 2022. A gradually growing prevalence of cancer warrants the use of the latest technology to enable oncologists better understand the mechanics of cancer and tumor cells and the application of NGS for DNA and RNA sequencing, epigenetics, and analyzing chromosomal abnormalities account for over three-fourths of the global sequencing data are factors responsible for high market share. Companies like Myriad, through its myRisk product, offer genetic testing to identify people who may be at higher risk of developing certain cancers in the future. In January 2021, Merus N.V.; a clinical-stage immuno-oncology company; collaborated with National Cancer Center, Japan, and Erasmus University Medical Center, Netherlands to evaluate its HER2/3-targeting bispecific antibody in solid tumors.

The academic research segment is anticipated to hold a majority of the Next-generation Sequencing Market size throughout the study period.

Based on end-user, the Next-generation Sequencing market is divided into academic research, clinical research, hospitals & clinics, pharma & biotech entities, and others. The academic research segment held the highest market share of xx% in 2022. The application of NGS solutions in research projects that are carried out in the universities and research centers can be attributed to the largest share of this segment in the market. Furthermore, scholarships offered for Ph.D. projects in NGS are anticipated to drive demand for NGS products and services, thereby resulting in lucrative growth over the forecast period. Provision of on-site bioinformatics courses that include workshops on the practical implementation of NGS sequencing and data analysis are also expected to boost revenue generated through the academic research segment in the coming years. Owing to the use of NGS in cancer research and, more specifically, in the discovery of new cancer-related genes, studying tumor heterogeneity, and identification of alterations that are contributive to tumorigenesis the segment is expected to witness significant growth through to 2028. In addition, the availability of clinical research solutions through market entities such as Illumina, Thermo Fisher Scientific Corporation, and Agilent Technologies for target enrichment and detection is anticipated to provide this segment with high growth opportunities over the forecast period.

The North America region is estimated to exhibit the highest growth rate during the Next-generation Sequencing Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the NGS market and accounted for the largest revenue share of xx% in 2022. The regional market is driven by the presence of multiple clinical laboratories that employ NGS to provide genetic testing services. Furthermore, due to the presence of high R&D investment, and the availability of a technologically advanced healthcare research framework, the development of WGS in the region is also expected to serve as a critical factor for the growth of the market in North America throughout the forecast period. In Asia Pacific, the market is estimated to grow fast over the forecast period owing to the presence of significant developments by China and Japan for technological integration of NGS methodologies, and the development of healthcare, R&D, and clinical development frameworks of emerging economies such as India and Australia have poised the Asia Pacific NGS market to witness lucrative opportunities of growth throughout the forecast period.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10518

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Next-generation Sequencing market include Agilent Technologies, Inc, BGI Group, F. Hoffmann-La Roche AG, Illumina Inc, Oxford Nanopore Technologies, Cepheid, PerkinElmer, Inc., Eurofins Scientific, Qiagen N.V., and Thermo Fisher Scientific Inc. among others..

Recent Developments in the Next-generation Sequencing Market:

  • In March 2021, Integrated DNA Technologies (IDT) announced the acquisition of Swift Biosciences, a pioneer in the development of NGS library preparation genomics kits for clinical, translational, and academic research
  • In January 2021, Cerba Research announced the launch of its new tools to enhance R&D for vaccine development against infectious diseases, including COVID-19.
  • In August 2020, Pediatrix Medical Group, GeneDx Inc., and OPKO Health signed an agreement to provide state-of-the-art, next-generation gene-sequencing to enhance clinical diagnosis in uncommon disorders for newborn intensive care unit.

Next-generation Sequencing Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Next-generation Sequencing Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Next-generation Sequencing Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Next-generation Sequencing Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Next-generation Sequencing Market Segmentation

By Workflow

  • Pre-sequencing
  • Sequencing
  • NGS Data Analysis

By Technology

  • WGS
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing

By Application

  • Oncology
  • Clinical Investigation
  • Reproductive Health
  • HLA Typing/Immune System Monitoring
  • Metagenomics, Epidemiology & Drug Development
  • Others

By End-user

  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Agilent Technologies, Inc
  • BGI Group
  • F. Hoffmann-La Roche AG
  • Illumina Inc
  • Oxford Nanopore Technologies
  • Cepheid
  • PerkinElmer, Inc.
  • Eurofins Scientific
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc.
Read More

Prenatal and New-born Genetic Testing Market
February, 2023

Prenatal and New-born Genetic Testing Market to Reach US$ 20.9 Bn by 2032, driven by rise in prevalence of genetic diseases in newborn babies, adoption of novel diagnostic methods for screening, improvement in healthcare facilities: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Prenatal and New-born Genetic Testing Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 20.9 Billion by 2032.

Prenatal testing provides you with information about your baby’s health. It detects any problems that could affect the health of fetuses like genetic defects and congenital conditions. Doctors recommend some prenatal tests while only a few women need special screening tests. Newborn testing is done to detect abnormalities that can cause certain health conditions such as inborn genetic defects. The genetic diseases that can be detected in newborns during screening are Down syndrome, phenylketonuria, homocystinuria, and others. Therefore it is important to diagnose genetic diseases in the early stages of the pregnancy and within 24 hours of newborn birth.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10516/

Prenatal and New-born Genetic Testing Market: Key Trends and Drivers

Growing consanguineous relations in African and Asian countries is expected to stimulate the market expansion

Growing rate of traditional consanguineous marriages that fuels the risk of autosomal recessive disorders in the newborn is amongst the key factors boosting the prenatal and new-born genetic testing market progression. Marrying in closely related family members is tradition in several countries in Middle East, West Asia, East Asia and North Africa region with almost half of the marriages being consanguineous. The emigrant from these regions continue the tradition and are contributing to the surging rates of genetic disorders. Consanguineous marriage results in transfer of two recessive defective mechanisms from the parents and the offspring may inherit these genes causing the congenital anomalies. Around 1 billion people reside in the countries that commonly practice marriage among relatives. Amongst them, 1 out of 3 individuals are married to a second cousin or closely related family member. The risk of having genetic defects or chromosomal abnormalities among offspring of such marriages is almost two-fold.

Prenatal and New-born Genetic Testing Market: Restraints & Challenges

The chances of miscarriage due to some of the prenatal testing is the main hurdle limiting the growth of the prenatal and newborn genetic testing market. For instance, amniocentesis is the most commonly performed non-invasive prenatal test during the second trimester of pregnancy have a chance of miscarriage. In addition, the high cost of screening methods and diagnostic tests is anticipated to hamper the growth of the market. For instance, chronic villus sampling costs around $3,050..

Prenatal and New-born Genetic Testing Market Report Findings

https://www.globalinsightservices.com/reports/prenatal-and-newborn-genetic-testing-market/

The diagnostics segment is likely to hold a dominant Prenatal and New-born Genetic Testing Market share and grow at a substantial CAGR during the forecast period.

On the basis of technology the market is segmented into diagnostics and screening. Among these screening segment of non-invasive prenatal testing (NIPT) is the largest and fastest-growing segment during the forecast period owing to, rise in awareness about prenatal testing and an increase in the number of pregnant women undergoing non-invasive prenatal testing (NIPT).

The diagnostic segment accounted for more than 35% of the prenatal and new-born genetic testing market share in 2022 led by the high accuracy and increasing utilization of prenatal diagnostic testing. Some diagnostic tests offer 99.9% precision in assessing the presence chromosomal abnormality in a baby. The emergence of fluorescence in situ hybridization (FISH) has been one of the cornerstones, promoting the use of diagnostic genetic testing amongst the infant population. Recent developments in novel approach have reduced the turnaround time for getting results and increased the accuracy in prenatal diagnosis, further reducing the occurrence of false-positive results.

The cystic fibrosis segment is anticipated to hold a majority of the Prenatal and New-born Genetic Testing Market size throughout the study period.

By disease, prenatal and the newborn genetic testing market is segregated into Down’s syndrome, phenylketonuria, cystic fibrosis, sickle cell anemia, and others. The Down syndrome segment dominated the global market in 2021. This is attributed to the fact that Down syndrome is one of the most prevalent chromosomal anomalies, thus a growing number of newborn babies suffering from Down syndrome increases the use of newborn genetic testing and augments the market growth.

The prenatal and new-born genetic testing market for cystic fibrosis segment exceeded USD 1.6 billion in 2022. Cystic fibrosis is a severe genetic disorder that damages the digestive and respiratory systems, further leading to life-threatening problems such as malnutrition, infections and respiratory failure among other complications. According to the Cystic Fibrosis Foundation, over 30,000 people in the U.S. and more than 70,000 globally are suffering from cystic fibrosis. On annual basis, around 1,000 cases of cystic fibrosis are diagnosed in the U.S. A research article published in the National Centers for Biotechnology Information (NCBI) states that the incidence of cystic fibrosis among the European population is 1 per 2,500 individuals. The incidence of this disorder is predicted to increase gradually in the coming years, further fostering the demand for prenatal and new-born genetic testing and offering the prenatal and new-born genetic testing market growth opportunities.

The Diagnostic Center segment is anticipated to hold a majority of the Prenatal and New-born Genetic Testing Market size throughout the study period.

By end user: the market is classified into hospitals, maternity and specialty clinics, and diagnostic centers. The hospital’s segment held the largest market share in 2021, owing to the availability of trained medical staff in hospitals that helps to provide better services to patients and it provides additional benefits of diagnosis and treatment of neuromuscular disorders including genetic conditions. On the other hand, maternity and specialty clinics is the fastest growing segment during the forecast period, as it offers complete pre-pregnancy and prenatal care which further reduces the risk of pregnancy complications.

The diagnostic centers segment in the prenatal and new-born genetic testing market is anticipated to expand at 11.3% growth rate through 2032 owing to the adoption of advanced prenatal and new-born genetic testing technologies and rapid clinical outcomes. The preference for diagnostic centers is increasing attributed to the high utilization of novel diagnostic tools offering accurate, quick and cost-effective clinical outcomes. Moreover, the growing number of diagnostic laboratories would further promote the segment growth.

The APAC region is estimated to exhibit the highest growth rate during the Prenatal and New-born Genetic Testing Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Asia Pacific market accounted for the largest revenue share in the global market in 2022. China held a significant revenue share in the Asia Pacific prenatal and new-born genetic testing market and is slated to expand at 15.1% CAGR by 2027 on account of the increasing prevalence of genetic conditions, rising occurrence of chromosomal malformations among the newborns and favorable government initiatives supporting prenatal and new-born genetic testing. The highly prevalent genetic conditions observed in the country are congenital hypothyroidism (CH), phenylketonuria (PKU), thalassemia and glucose-6-phosphate dehydrogenase (G6PD) deficiency among others. Approximately 5.6% of the infants in the country are born with defects and the rate has increased over the time significantly.

Additionally, as per the estimates, around 26,000 new cases of Down’s syndrome are added on an annual basis with incidence of Down’s syndrome accounting for 1 out of 700 births. The government initiatives in place favor the prenatal and new-born genetic testing across the country. Three surveillance programs are initiated by the government for detecting birth defects: National Statistic of Health, National Birth Registry and National birth defect registry. The Chinese government also mandates screening for phenylketonuria and congenital hypothyroidism among the infants under newborn screening program.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10516/

Competitive Landscape

The global Prenatal and New-born Genetic Testing Market report includes players are Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad, Illumina, Laboratory Corporation of America, Natera, Qiagen, Sequenom, Trivitron Healthcare and Verinata Health among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In August 2022, F. Hoffman-La Roche AG has launched the Digital LightCycler System a next-generation digital PCR system that helps physicians to better understand the nature of genetic diseases.
  • In August 2022, Natera Inc. filed a pre-submission to the Food and Drug Administration (FDA) for its panorama non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and 22q11.2 deletion syndrome.
  • In July 2022, Genetic Technologies Limited acquired EasyDNA as the company expanded the availability on its websites of Carrier Testing and Non-Invasive Prenatal Tests (NIPT) in Europe.

Prenatal and New-born Genetic Testing Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Prenatal and New-born Genetic Testing Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Prenatal and New-born Genetic Testing Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Prenatal and New-born Genetic Testing Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Prenatal and New-born Genetic Testing Market Segmentation

By Technology

  • Screening
  • Diagnostics

By Disease

  • Downs Syndrome
  • Phenylketonuria
  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Others

By End-use

  • Hospitals
  • Maternity & Specialty Clinics
  • Diagnostic Centers

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Ariosa Diagnostics (Roche)
  • Berry Genomics
  • BGI
  • Biorad
  • Illumina
  • Laboratory Corporation of America
  • Natera
  • Qiagen
  • Sequenom
  • Trivitron Healthcare
  • Verinata Health

 

Read More

Metagenomics Market
February, 2023

Metagenomics Market to Reach US$ 6.3 Bn by 2032, driven by increasing implementation of DNA sequencing across metagenomic applications coupled with rapid adoption of novel sequencing technologies: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Metagenomics Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 6.3 Billion by 2032.

Metagenomics comprises studies that use sequencing technologies and bioinformatics tools to obtain useful insights on the diversities in the microbial community and interaction of the microbes in a community. Metagenomic technologies have enabled improved understanding of the microbial ecology and the role of microbiology in the global geochemical cycles through functional metagenomics. In addition, metagenomic studies have allowed researchers to tap into a vast microbial diversity, which was left unaddressed with the conventional microbiology methods..

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10517

Metagenomics Market: Key Trends and Drivers

The growth of the global metagenomics sequencing market is majorly driven by growth in demand for drug discovery, clinical diagnostics, and increase in prevalence of genetic disorder. In addition, metagenomic technologies enable the study of microbial communities as entire units without entailing the need of cultivating them. As uncultivability and genomic diversity serve as the two major roadblocks in the advancements of environmental and clinical microbiology, metagenomics has gained immense traction among the healthcare professionals and researchers. The advancement in metagenomics sequencing technologies is projected to increase the growth opportunities for the metagenomics sequencing market.

Metagenomics Market: Restraints & Challenges

Conversely, because metagenomics is a relatively new concept involving analysis of interaction in the microbe community and its interpretation, lack of knowledge regarding this sector is expected to hamper the market growth.

Metagenomics Market Report Findings

https://www.globalinsightservices.com/reports/metagenomics-market/

The Kits & Reagents segment is likely to hold a dominant Metagenomics Market share and grow at a substantial CAGR during the forecast period.

Based on Product, the market is bifurcated into Kits & Reagents, Sequencing & Data Analytics Services, and Software. Kits and reagents dominate the metagenomics market with the largest share in 2022. A variety of reagents are employed in sequencing during the experimental preparation of the sample. The market comprises established companies such as F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, and Illumina Inc. with a wide range of reagents to match the requirements in sequencing.

On the other hand, sequencing and data analytics services are estimated to report the fastest growth. This is attributed to the increase in the adoption of sequencing leads to a higher demand for data analysis platforms. Similarly, Companies are either providing services to perform metagenomics data interpretation or introducing products in the market so that research entities are involved in clinical practice. For instance, ArrayGen Technologies Pvt. Ltd. offers a wide range of NGS data analysis services in the field of cancer genomics, disease association studies, agriculture biotechnology, and personalized medicine. The company utilizes 454, Illumina, Ion-Torrent, SOLID, Nanopore, PacBio, and other platforms to provide services for de novo assembly of transcriptome and genome, metatranscriptome analysis, Comparative Genomics Analysis (CGA) & annotation, 16S/28S/ITS rRNA metagenomic analysis, and custom arrays for validation of NGS data.

The shotgun sequencing segment is anticipated to hold a majority of the Metagenomics Market size throughout the study period.

Based on the technology, the market is bifurcated into Shotgun Sequencing, 16S Sequencing, Whole Genome Sequencing, Others. The shotgun sequencing segment is projected to register a substantial CAGR from 2022 to 2032. Numerous academic institutions and research centers are adopting technology for their genetic studies. For instance, in July 2022, an article published on the portal of Arthritis & Rheumatology stated that the background of genetics along with disease activity impacts the composition of gut microbiota. The study performed shotgun sequencing to derive the conclusion.

Whole genome sequencing, on the other hand, has projected significant growth in the industry during the forecast period. Companies are making focused efforts to expand their business operations in the clinical rare disease diagnosis space. For instance, in June 2021, Rady Children’s Institute for Genomic Medicine partnered with Pacific Biosciences for research related to whole-genome sequencing. The initiatives aim to detect possible disease-causing genetic variants and increase the solve rates of rare disorders..

The Environmental segment is anticipated to hold a majority of the Metagenomics Market size throughout the study period.

Based on the application, the market is bifurcated into Environmental, Clinical Diagnostics, Drug Discovery, Biotechnology, Food & Nutrition, Others. The environmental segment captured the highest revenue share in 2021. Metagenomics research is rapidly developing its space in agriculture and environmental protection. Metagenomics is a new technique to understand microorganisms received from a particular environment through sequencing analysis or gene screening. According to the research conducted by Capital Medical University and Peking University Ditan Teaching Hospital in December 2021, next-generation sequencing and third-generation sequencing have showcased the advantages of rapid identification of pathogenic microorganisms. Furthermore, clinical diagnostics is the emerging application of metagenomics with the fastest CAGR during the forecast period. Along with the diagnostics of infectious diseases, the adoption of metagenomics in clinical laboratories is also increasing and various applications have been incorporated into a regular practice of clinical.

The North America region is estimated to exhibit the highest growth rate during the Metagenomics Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the North America market accounted for the largest revenue share in the global market in 2022. This dominance can be determined by the existence of key companies in the region with an increased circulation of funds in R&D, coupled with advancements in sequencing technology. The market witnessed collaboration between companies and academic institutions and is one of the key strategies used in the region. For instance, in September 2021, the Broad Institute established a partnership with the CDC and Theiagen Genomics to accelerate support for public health labs in the U.S. The primary focus of the partnership is to enable the surveillance of pathogen genomics around the U.S.

The Asia Pacific region is anticipated to witness the fastest growth during the forecast period owing to the extensive developments by India and China in the adoption of metagenomics in numerous applications. The increasing focus on genomics and proteomics research, coupled with increasing strategic initiatives by academic institutions for innovative development in sequencing have impacted the Asia Pacific market of metagenomics with lucrative growth opportunities throughout the forecast period.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10517/

Competitive Landscape

The global Metagenomics Market report includes players are Bio-Rad Laboratories; Illumina, Inc.; PerkinElmer, Inc.; Thermo Fisher Scientific, Inc.; Novogene Co., Ltd.; Promega Corporation; QIAGEN; Takara Bio, Inc.; Oxford Nanopore Technologies; and F. Hoffmann-La Roche Ltd..

Recent Developments in the Blood-Brain Barrier Market:

  • In September 2022, Illumina, Inc. announced to invest in six genomics startups from the U.K., South Africa, Ireland, Israel, Indonesia, and the U.S. As of September 2022, the company has invested in 74 genomics-based startups. Along with the seed investment, access to business guidance, Illumina’s sequencing reagents and systems, operational labs, and genomics expertise are offered to the startups.
  • In August 2022, OpGen, Inc., a personalized medicine company, announced to launch of next-generation sequencing (NGS) services under the subsidiary, Ares Genetics.
  • In September 2021, the Broad Institute established a partnership with the CDC and Theiagen Genomics to accelerate support for public health labs in the U.S. The primary focus of the partnership is to enable the surveillance of pathogen genomics around the U.S
  • In June 2021, Rady Children’s Institute for Genomic Medicine partnered with Pacific Biosciences for research related to whole-genome sequencing. The initiatives aim to detect possible disease-causing genetic variants and increase the solve rates of rare disorders.
  • In February 2021, QIAGEN extended its collaboration with INOVIO Pharmaceuticals for the development of liquid biopsy-based CDx products that can deploy the NGS method to complement INOVIO’s therapy, VGX-3100. VGX-3100 is an immunotherapy designed for the treatment of advanced cervical dysplasia associated with HPV. This initiative is anticipated to strengthen clinical applications of metagenomics.

Metagenomics Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Metagenomics Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Metagenomics Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Metagenomics Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Metagenomics Market Segmentation

By Product

  • Kits & Reagents
  • Sequencing & Data Analytics Services
  • Software

By Technology

  • Shotgun Sequencing
  • 16S Sequencing
  • Whole Genome Sequencing
  • Others

By Application

  • Environmental
  • Clinical Diagnostics
  • Drug Discovery
  • Biotechnology
  • Food & Nutrition
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Bio-Rad Laboratories
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.
  • Novogene Co., Ltd.
  • Promega Corporation
  • QIAGEN
  • Takara Bio, Inc.
  • Oxford Nanopore Technologies
  • F. Hoffmann-La Roche Ltd.
Read More

Whole Exome Sequencing Market
February, 2023

Whole Exome Sequencing Market to Reach US$ 7.4 Bn by 2032, driven by increasing investments in research-based projects and growing alliances among leading companies and research centers for drug discovery, and increasing inclination toward next-generation sequencing methods for identifying, treating, and monitoring chronic diseases: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Whole Exome Sequencing Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 7.4 Billion by 2032.

Exome sequencing is a method for sequencing a genomes whole-exome and protein-coding genes. This method entails selecting the DNA segments that code for proteins or exons, then sequencing the exonic DNA with high-throughput DNA sequencing technologies. Exome sequencing is a technique for identifying genetic variations that cause disorders like Miller Syndrome and Alzheimers disease.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10515/

Whole Exome Sequencing Market: Key Trends and Drivers

The rising applications in clinical diagnostics, high demand for the diagnosis of rare diseases, expanding R&D in the field of genomics, next-generation sequencing, and increasing need for customized medicine are the key factors driving the global Whole Exome Sequencing Market. The total market is being driven by growth in the acceptability of next-generation sequencing approaches for the prediction, treatment, and monitoring of a variety of chronic diseases, such as cancer. The total market is being driven by growth in the acceptability of next-generation sequencing approaches for the prediction, treatment, and monitoring of a variety of chronic diseases, such as cancer. Some of the primary driving reasons for the worldwide Whole Exome Sequencing Market include the cheap costs and increased speed associated with whole-exome sequencing techniques, technological improvements in whole-exome sequencing techniques, and global partnerships among prominent research institutes..

Whole Exome Sequencing Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Whole Exome Sequencing Market Report Findings

https://www.globalinsightservices.com/reports/whole-exome-sequencing-market/

The kits segment is likely to hold a dominant Whole Exome Sequencing Market share and grow at a substantial CAGR during the forecast period.

Based on Product, the market is bifurcated into Systems, Kits, and Services. Systems accounted for the largest market share of xx% in 2022 and are projected to grow at a CAGR of xx% during the forecast period. Kits were the second-largest market in 2022, it is projected to grow at the highest CAGR of xx%. The growth can be attributed to the frequent use of kits in various research processes and a large number of manufacturers involved in product development, including Illumina, Thermo Fisher Scientific, and others. Nextera Rapid Capture Exomes are all-in-one kits for library preparation and exome enrichment that allow researchers to identify coding variants up to 70% faster than other methods.

The Second-Generation Sequencing segment is anticipated to hold a majority of the Whole Exome Sequencing Market size throughout the study period.

Based on the technology, the market is bifurcated into Second-Generation Sequencing, and Third-Generation Sequencing. Second-Generation Sequencing accounted for the largest market share in 2022 and is projected to grow at a CAGR of xx% during the forecast period. Second generation sequencing methods can be grouped into two major categories, sequencing by hybridization and sequencing by synthesis (SBS). Common applications include whole-genome sequencing, target resequencing, characterization of structural and copy number variation, profiling epigenetic modifications, transcriptome sequencing and identification of infectious agents. Second-generation sequencing generates short reads (of length < 300bp) and these are highly accurate (sequencing error rate equals ∼1%). Short read sequencing technologies have made sequencing much easier, a lot faster and much cheaper than Sanger sequencing.

The Diagnstics segment is anticipated to hold a majority of the Whole Exome Sequencing Market size throughout the study period.

Based on the application, the market is bifurcated into Diagnostics, Drug Discovery and Development, Personalized Medicine, Agriculture and Animal Research, and Others. Diagnostics accounted for the largest market share in 2022 and is projected to grow at a CAGR of xx% during the forecast period. This method allows variations in the protein-coding region of any gene to be identified, rather than in only a select few genes. Because most known mutations that cause disease occur in exons, whole exome sequencing is thought to be an efficient method to identify possible disease-causing mutations. Whole exome sequencing is a type of genetic sequencing increasingly used to understand what may be causing symptoms or a disease. Genetic testing has already been used for a long time in some health areas, such as cancer diagnosis and prenatal screening. Drug Discovery and Development was the second-largest market in 2022..

The North America region is estimated to exhibit the highest growth rate during the Whole Exome Sequencing Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the North America market accounted for the largest revenue share in the global market in 2022. North America has a large regional market in terms of revenue. The increasing prevalence of genetic and chronic disorders, such as cancer, the aging population, the growing demand for targeted and personalized medicine, and favorable government initiatives are the primary factors behind the growth of the whole-exome sequencing market. According to the HIV.gov updates in October 2022, HIV affects around 1.2 million persons in the United States. In the United States, in 2020, 30,635 persons were diagnosed with HIV. Thus, the growing burden of infectious diseases is expected to increase in demand for its diagnosis, thereby boosting the market’s growth over the forecast period.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10515/

Competitive Landscape

The global Whole Exome Sequencing Market report includes players are Ambry Genetics Corp. Bio-Rad Laboratories Inc., Eurofins Scientific Group, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Boston Scientific Corporation, QIAGEN, OraSure Technologies, Inc., Thermo Fisher Scientific, Helix OpCo, LLC, among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In May 2022, the Qatar Genome Program (QGP), a division of the Qatar Foundation (QF), and Thermo Fisher Scientific entered into a partnership to advance genomic research and clinical applications of predictive genomics in Qatar as a step toward extending the advantages of precision medicine across Arab populations.
  • In May 2021, BG introduced Rapid Trio Whole Exome Sequencing, which reduced turnaround time from seven to five days. In June 2021, Centogene N.V., a commercial-stage company that generates data-driven insights to diagnose, understand, and cure rare diseases, launched NEW CentoXome, an improved next-generation sequencing-based assay. Thus, due to the factors mentioned above, such as the growing prevalence of infectious diseases and product launches, the market is expected to show significant growth over the forecast period in the region
  • In January 2021, OraSure Technologies, Inc. launched Oragene Dx (OGD-610) saliva collection device. It was included as a component in the De Novo authorization granted by the United States Food and Drug Administration (USFDA) to Helix for their Helix Laboratory Platform, a whole exome sequencing platform. The first exome sequencing-based platform authorized by the United States Food and Drug Administration (USFDA).
  • In January 2021, Illumina Inc. announced a portfolio of new and expanded oncology partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to advance comprehensive genomic profiling for precision oncology.
  • In June 2021, Labcorp and OmniSeq, a CAP-accredited molecular diagnostic innovation of Roswell Park Comprehensive Cancer Center, announced the launch of OmniSeq INSIGHTsm, a comprehensive genomic and immune profiling, tissue-based test that integrates next-generation sequencing (NGS) technology.

Whole Exome Sequencing Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Whole Exome Sequencing Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Whole Exome Sequencing Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Whole Exome Sequencing Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Whole Exome Sequencing Market Segmentation

By Product

  • System
  • Kits
  • Services

By Technology

  • Second-Generation Sequencing
  • Third-Generation Sequencing

By Application

  • Diagnostics
  • Drug Discovery and Development
  • Personalized Medicine
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Ambry Genetics Corp.
  • Bio-Rad Laboratories Inc
  • Eurofins Scientific Group
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific Inc.
  • Boston Scientific Corporation
  • QIAGEN
  • OraSure Technologies, Inc.
  • Thermo Fisher Scientific
  • Helix OpCo, LLC
Read More

Nucleic Acid Amplification Testing Market
February, 2023

Nucleic Acid Amplification Testing Market to Reach US$ 3.8 Bn by 2032, driven by Increase in demand for the advanced rapid diagnostics and rising R&D investments for the development of novel biotechnological diagnostic techniques: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Nucleic Acid Amplification Testing Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 3.8 Billion by 2032.

A Nucleic Acid Amplification Test, or NAAT, is a type of viral diagnostic test for SARS-CoV-2, the virus that causes COVID-19. NAATs detect genetic material (nucleic acids). NAATs for SARS-CoV-2 specifically identify the RNA (ribonucleic acid) sequences that comprise the genetic material of the virus.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10512/

Nucleic Acid Amplification Testing Market: Key Trends and Drivers

Increase in demand for the advanced rapid diagnostics and rising R&D investments for the development of novel biotechnological diagnostic techniques are the factors fueling the market growth. In addition, high global prevalence of the communicable diseases and need for the highly efficient testing alternatives for the successful management of disease outbreaks has propelled demand for the several nucleic acid amplification testing technologies. Emerging infectious diseases, such as the Monkeypox virus, are opening new avenues for market growth and is evident by the launch and regulatory approval of nucleic acid amplification test products for such diseases. For instance, in September 2022, Quest Diagnostics received the U.S. FDA’s Emergency Use Authorization (EUA) for its Quest Monkeypox PCR test launched in July 2022. Similarly, in August 2022, Todos Medical Ltd. commercially launched its Monkey Pox PCR-based test in the U.S. Hence, such novel infections are expected to further expand the market growth.

Nucleic Acid Amplification Testing Market: Restraints & Challenges

There are several key restraints and challenges in the Nucleic Acid Amplification Testing market. First, encryption can be a complex and resource-intensive process, particularly for large banks with thousands of customers and transactions. Second, encryption can also be vulnerable to attack, and banks must constantly update and improve their encryption software to stay ahead of the latest threats. Finally, encryption can also impede the ability of law enforcement and other government agencies to access data for criminal investigations, which can be a major challenge in some cases.

Nucleic Acid Amplification Testing Market Report Findings

https://www.globalinsightservices.com/reports/nucleic-acid-amplification-detection-and-diagnostics-market/

The PCR tests segment is likely to hold a dominant Nucleic Acid Amplification Testing Market share and grow at a substantial CAGR during the forecast period.

By type, the market is segmented into Polymerase Chain Reaction (PCR) tests, Isothermal Nucleic Acid Amplification Technology (INAAT) tests, and Ligase Chain Reaction (LCR) tests. The PCR tests segment recorded the largest market share of xx% in 2022. The technology enables rapid and sensitive detection of a broad range of target nucleic acid molecules and can be used for the detection of specific pathogens that may be difficult to culture in vitro. In addition, widespread penetration of PCR technology has enabled applications of the technique for the detection, quantification, and genotyping of a variety of bacteria and viruses from several types of clinical specimens, including plasma, serum, semen, cerebrospinal fluid, and others. As a result, the PCR tests segment is expected to witness significant growth during the forecast period.

The Isothermal Nucleic Acid Amplification Technology (INAAT) tests segment is projected to expand at a rapid CAGR during the forecast period due to the introduction of novel technologies, such as loop-mediated isothermal amplification (LAMP), strand displacement amplification, and recombinase polymerase amplification, among others, that are broadening the scope of the applications for nucleic acid-based test products. For instance, in June 2022, a research study published in the Analyst Journal demonstrated a new smartphone-integrated technology that can perform rapid Zika virus testing in a single blood drop with the help of the LAMP technology. Such advancements are anticipated to drive the segment and positively affect market growth.

The infectious disease segment is anticipated to hold a majority of the Nucleic Acid Amplification Testing Market size throughout the study period.

By application, the Nucleic Acid Amplification Testing Market is classified into Infectious Disease Testing, Oncology Testing, Genetic & mitochondrial disease testing, and Others. The infectious disease segment held the largest market share of xx% in 2021. This can be attributed to the widespread prevalence and rising incidence rate of infectious diseases such as influenza, sexually transmitted infections, and others. The COVID-19 testing sub-segment held the largest share in 2021 within the infectious disease testing segment due to the global presence of the pandemic and the launch of several new PCR tests. For instance, in October 2020, Euro fins Central Laboratory launched its Empower DX SARS CoV 2 RT PCR test with the option for at-home sampling. Such product launches are expected to increase the market penetration of PCR tests and drive segment growth.

Oncology testing segment is projected to expand at the fastest CAGR during the forecast period due to the rise in R&D interests for the development of novel cancer diagnostic alternatives and rapid progress in cancer research. For instance, in March 2022, researchers from Queen Mary University of London announced the development of the first PCR test for the detection of oral cancer. Such advancements are likely to fuel growth prospects for the nucleic acid amplification testing of other ontological conditions in the near future.

The central and reference laboratories segment is anticipated to hold a majority of the Nucleic Acid Amplification Testing Market size throughout the study period.

The end-use. Market is segmented ino Hospitals, Central and reference laboratories, and Others. The central and reference laboratories segment dominated the market in 2022 due to its extensive testing portfolio and coverage across multiple healthcare settings. In addition, supportive government initiatives are aiding in the expansion of the testing capacities of such laboratories. For instance, in June 2022, the Department of Health and Human Services (HHS) expanded the Monkeypox testing capacity to five laboratory companies, including Lab corp., Quest Diagnostics, Mayo Clinic Laboratories, Aegis Science, and Sonic Healthcare.

Hospitals segment is expected to grow at the fastest CAGR of xx% by 2032. The rise in healthcare expenditure globally and the increasing role of nucleic acid amplification techniques for disease surveillance and prevention of outbreaks are the factors leading to the growth of the segment. Similarly, growth in hospital testing capacities post-COVID-19 and availability of the high throughput testing capabilities can considerably boost the market prospects for nucleic acid amplification testing.

The North America region is estimated to exhibit the highest growth rate during the Nucleic Acid Amplification Testing Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America held the largest revenue share of over 28.0% in 2021. North America accounted for the largest market share xx% in 2022 due to the high extent of chronic disease prevalence and the presence of an established research and healthcare infrastructure. Similarly, demand for nucleic acid amplification tests is also driven by the increasing focus on point-of-care diagnostic methods and the high extent of disease prevention measures in the region. Asia Pacific is expected to grow at the fastest rate during the forecast period due to the existence of a large population and rising focus on the healthcare systems. High incidence of emerging infectious diseases such as Japanese encephalitis, Hendra, and Nipah virus infections can strengthen the market prospects for nucleic acid amplification testing.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10512/

Competitive Landscape

The key players in the Nucleic Acid Amplification Testing Market F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Danaher Corporation; Abbott Laboratories; Illumina, Inc.; Siemens Healthineers; bio Mérieux SA; Novartis AG; Bio-Rad Laboratories, Inc., See gene Inc, among others.

Recent Developments in the Nucleic Acid Amplification Testing Market:

  • September 2022, Mylab Discovery Solutions debuted their Patho Detect HPV Identification PCR Test for the detection of human papillomavirus (HPV) in high-risk patients.
  • Abingdon Health announced a new version of the successful NALFIA fast test in January 2019 for the detection of DIG/Biotin and/or FITC (Or FAM)/biotin-labeled analytes.
  • In September 2018, researchers at the National University of Singapore created a portable platform for a point-of-care nucleic acid test that can be used to diagnose a variety of diseases. “enVision” is the name of the device (enzyme-assisted nanocomplexes for visual identification of nucleic acids).
  • In September 2018, researchers at the National University of Singapore created a portable platform for a point-of-care nucleic acid test that can be used to diagnose a variety of diseases. “enVision” is the name of the device (enzyme-assisted nanocomplexes for visual identification of nucleic acids).

Nucleic Acid Amplification Testing Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Nucleic Acid Amplification Testing Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Nucleic Acid Amplification Testing Market potential from 2022 to 2032 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Nucleic Acid Amplification Testing Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Nucleic Acid Amplification Testing Market Segmentation

By Type

  • Polymerase Chain Reaction (PCR) tests
  • Isothermal Nucleic Acid Amplification Technology (INAAT) tests
  • Ligase Chain Reaction (LCR) tests

By Application

  • Infectious Disease Testing
  • Oncology Testing
  • Genetic & mitochondrial disease testing
  • Others

By End-use

  • Hospitals
  • Central and reference laboratories
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • F. Hoffmann-La Roche Ltd
  • Becton, Dickinson and Company
  • Danaher Corporation
  • Abbott Laboratories
  • Illumina, Inc.
  • Siemens Healthineers
  • bio Mérieux SA
  • Novartis AG
  • Bio-Rad Laboratories, Inc.
  • See gene Inc.

 

Read More

Sanger Sequencing Market
February, 2023

Sanger Sequencing Market to Reach US$ 13.4 Bn by 2032, driven by Rapid advancements in sequencing technology and bioinformatics have enabled the identification of DNA variations. These advancements also determine variants associated with increased risk for disease: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global Sanger Sequencing Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 13.4 Billion by 2032.

The Sanger technique of DNA sequencing relies on the random incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication and uses electrophoresis. However, for smaller-scale initiatives and for validating the outcomes of deep sequencing, the sanger approach is still widely used. It can still create DNA sequence reads of more than 500 nucleotides and maintain accuracy levels around 99.99 percent, giving it an edge over short-read sequencing methods (like Illumina).

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10514/

Sanger Sequencing Market: Key Trends and Drivers

The market for Sanger’s sequencing services is expanding due to technological developments in sequencing methods, benefits of Sanger’s sequencing, and an increase in genome mapping initiatives. Additionally, sequencing applications and R&D expenditure boost have added to the market’s expansion.

Research and development (R&D) activities

The increased attention that vendors are paying to developing economies like China, India, and Southeast Asia is anticipated to promote market expansion. The market is expected to experience significant growth in the near future as a result of rising R&D spending and a boom in sanger sequencing applications.

Rise in genetic illness

The expanding use of genetic testing on vertebrates and plants, other factors influencing the market’s growth include the rising prevalence and familiarity of genetic illnesses and tailored medicine. During the forecast period of 2022 to 2029, a few factors have the potential to propel market expansion.

Sanger Sequencing Market: Restraints & Challenges

There are a few key restraints and challenges in Sanger Sequencing market. The lack of compensation due to the strict restrictions for next-generation sequencing research, the lack of skilled professionals or one might even say a still-evolving business, can operate as a restraint on the market’s growth.

Sanger Sequencing Market Report Findings

https://www.globalinsightservices.com/reports/sanger-sequencing-market/

The Shotgun Sequencing segment is likely to hold a dominant Sanger Sequencing Market share and grow at a substantial CAGR during the forecast period.

By sequencing, the market is segmented into Shotgun Sequencing, Targeted Gene Sequencing, and Others. Shotgun sequencing segment accounted for largest market share in 2022. This is attributed to the shotgun sequencing is a laboratory technique for determining the DNA sequence of an organism’s genome. The method involves randomly breaking up the genome into small DNA fragments that are sequenced individually. metagenomic shotgun sequencing workflow offers fully automated soil sample preparation, sequencing, and analysis, to help researchers characterize soil microbial communities. The growth of the global metagenomics sequencing market is majorly driven by growth in demand for drug discovery, clinical diagnostics, and increase in prevalence of genetic disorder. In addition, metagenomic technologies enable the study of microbial communities as entire units without entailing the need of cultivating them. As uncultivability and genomic diversity serve as the two major roadblocks in the advancements of environmental and clinical microbiology, metagenomics has gained immense traction among the healthcare professionals and researchers. The advancement in metagenomics sequencing technologies is projected to increase the growth opportunities for sequencing market.

The Diagnostic segment is anticipated to hold a majority of the Sanger Sequencing Market size throughout the study period.

By application, the Sanger Sequencing Market is classified into Diagnostics, Biomarkers, Cancer, Reproductive Health, Personalized Medicine, Forensics, and Others. Of these the Diagnostic segment dominated the market and accounted for the maximum revenue share of xx% in 2021. The technology holds great potential in clinical research and development of cancer diagnostics and therapeutics. Recently, NGS technology has demonstrated the capacity as a high-throughput and an affordable approach in the identification and characterization of clinically actionable genetic variants across numerous genes at an exceptional speed in a single test.

Furthermore, the value of these technologies in companion diagnostics and precision medicine is widely recognized by clinicians and companies. In regard to this, in August 2020, the FDA approved the first liquid biopsy companion diagnostic that leverages NGS technology to guide cancer treatment. The Guardant360 CDx assay promotes less invasive testing and the simultaneous mapping of several biomarkers of genomic alterations in the tumor.

The Research Institutes segment is anticipated to hold a majority of the Sanger Sequencing Market size throughout the study period.

Based on end-use. It is segmented into Academic, Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Hospitals, and Clinics. In 2022, research and academic institutes led the market with a revenue share of over 50.0%. The growth is attributed to the increased R&D studies conducted by academic institutes using miRNA sequencing techniques. Moreover, wide acceptability of Sanger technology and NGS in academic and institutional research projects. Besides, a rise in funding and investment programs augment the demand for DNA sequencing products in these entities, resulting in a larger revenue share. For instance, in January 2020, the Intelligence Advanced Research Projects Activity provided USD 23.0 million to the Broad Institute and Harvard University, and DNA Script. The entities are working together to explore the possibility of combining the enzymatic DNA synthesis technology and NGS into a single instrument for more than four years. This consortium further plans to partner with Illumina to utilize its sequencing-by-synthesis technology.

The North America region is estimated to exhibit the highest growth rate during the Sanger Sequencing Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the market with a revenue share of over xx% in 2022. This is attributed to the increase in implementation of DNA sequencing across metagenomics applications in this region. In addition, rapid adoption of novel sequencing technologies in this region has contributed to its dominance. Increase in acquisition, product launch, and product approval by key players of this market operate in North America turn, fuels growth of the market. In Asia Pacific, the market is projected to witness a lucrative growth rate throughout the forecast period. Strategic initiatives undertaken by international firms to expand their presence due to the high customer base is expected to create numerous opportunities for regional growth. For instance, in February 2020, GenapSys, a California-based firm, raised USD 75 million to finance the global expansion of its tabletop DNA sequencer to support the control of coronavirus in the region.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10514/

Competitive Landscape

The key players in the Sanger Sequencing Market are Thermo Fisher Scientific Inc (U.S.), Source BioScience (U.K.), GenScript (U.S.), LGC Limited (U.K.), CeMIA (U.S.),, Quintara Biosciences (U.S.), GenHunter Corporation (U.S.), GENEWIZ (U.S.), , Nucleics (U.K.), SciGenom Labs Pvt. Ltd (India), Microsynth AG (Switzerland), Eurofins Scientific (Luxembourg), LGC Limited (U.K.)among others.

Recent Developments in the Sanger Sequencing Market:

  • In August 2020, Illumina Inc. launched NovaSeq 6000 v1.5 Reagent Kit, which made the WGS technique more cost-effective and accessible for all the laboratories and reduced the cost to sequence a human genome for USD 600. These new kits can be used across WGS, single-cell genomics, and liquid biopsy techniques.
  • In June 2020, Illumina received Emergency Use Authorization (EUA) from the FDA for its COVIDSeq Test that is used to sequence the full genome of the novel SARS-CoV-2 virus. This test along with high-throughput NovaSeq 6000 hardware of Illumina is capable of processing more than 3,000 samples and offers results within 24 hours.
  • In April 2020, Helix OpCo LLC received EUA for its Helix COVID-19 NGS Test for the detection of SARS-CoV-2 infection
  • In February 2020, GenapSys, a California-based firm, raised USD 75 million to finance the global expansion of its tabletop DNA sequencer to support the control of coronavirus in the region
  • In June 2019, PerkinElmer, Inc. along with FDNA, an artificial intelligence company, introduced Face2Gene LABS to provide genomic services, in combination with Next-Generation Phenotyping (NGP) technologies for more accurate and efficient diagnoses.

Sanger Sequencing Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Sanger Sequencing Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Sanger Sequencing Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Sanger Sequencing Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Sanger Sequencing Market Segmentation

By Sequencing

  • Shotgun Sequencing
  • Targeted Gene Sequencing
  • Others

By Application

  • Diagnostics
  • Biomarkers
  • Cancer
  • Reproductive Health
  • Personalized Medicine
  • Forensics
  • Others

By End-user

  • Academic
  • Government Research Institutes
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Hospitals
  • Clinics

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Thermo Fisher Scientific Inc (U.S.)
  • Source BioScience (U.K.)
  • GenScript (U.S.)
  • LGC Limited (U.K.)
  • CeMIA (U.S.),
  • Quintara Biosciences (U.S.)
  • GenHunter Corporation (U.S.)
  • GENEWIZ (U.S.), Nucleics (U.K.)
  • SciGenom Labs Pvt. Ltd (India)
  • Microsynth AG (Switzerland)
Read More

Digital Genome Market
February, 2023

Digital Genome Market to Reach US$ 64.6 Bn by 2032, driven by rising incidence of chronic diseases, such as cancer, increasing government entities’ investment in research, raising awareness of patients, and the availability of advanced healthcare infrastructure: Global Insight Services

New York, January 2023: According to a new research study by Global Insight Services (GIS), the global Digital Genome Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 64.6 Billion by 2032.

Digital genome can be used in the diagnosis of rare diseases, genetic diseases, cancer, neurological disorders and others. A digital genome is a digital set of genetic materials that transpires in an organism. It is regarded as a convenient way to collect data regarding chronic diseases and is widely practiced by experts to achieve a closer look at genetic complications.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10511/

Digital Genome Market: Key Trends and Drivers

Surge in adoption of precision medicine will remain a key growth driver

The demand for digital genome is rapidly gaining popularity owing to continuous reduction in the cost and time required. The sequencing is widely used in the field of oncology, reproductive health and genetics. As a result, firms such as Illumina, Thermo Fisher and Qiagen are developing new innovative technologies in the field of genomics. Digital genomics market will further grow as rising application of sequencing in diagnosis of genetic disorders such as Duchenne Muscular Dystrophy, Fragile X syndrome and FAM Hypercholesterolemia etc. Advent of new technology coupled with rising demand of precision medicines will escalate market over forecast period. The major factors limiting the growth of digital genome market is lack of awareness regarding the digital genome, security & privacy of patient data, and incorrect results. In addition, lack of trained staff for digital genome in various developing economies will further impede the industry growth.

Digital Genome Market: Restraints & Challenges

There are a few key restraints and challenges in Digital Genome market. Whole-genome sequencing can be less efficient at predicting some conditions than biochemical tests. This means that WGS would need to be combined with the existing screening process, rather than replacing it. Moreover, the test is limited in its ability to detect mosaicism. This technology is limited in its ability to accurately identify variants occurring in regions with high sequence identity to other regions of the genome.

Digital Genome Market Report Findings

https://www.globalinsightservices.com/reports/digital-genome-market/

The DNA/RNA Analysis Kits segment is likely to hold a dominant Digital Genome Market share and grow at a substantial CAGR during the forecast period.

By product, the market is segmented into Sequencing & Analyzer Instruments, DNA/RNA Analysis Kits, Sequencing Chips, Sequencing & Analysis Software, and Sample Preparation Instruments. The market for DNA/RNA analysis kits are growing rapidly. With increasing investments and funding for research on life science, the adoption of digital genome is growing rapidly. Furthermore, high demand for various genotypic analysis and protein analysis are significantly contributing towards demand of digital genomics. The key players operating in the market have further developed advanced process of analysis of genes. With escalating research for genetics, stem cells and oncology, the need for DNA / RNA analysis kits will increase over estimated time frame. The key players of market, Thermo Fisher Scientific, GenomeMe, BiogeniQ and Nanostring has a wide array of kits for tumor gene analysis. The companies have developed kits where quantification of protein as well as analysis of gene expression can be performed in one experiment. The increasing demand for tumor gene analysis and advanced platforms will further propel demand for genome in near future.

The Reproductive & Genetic segment is anticipated to hold a majority of the Digital Genome Market size throughout the study period.

By application, the Digital Genome Market is classified into Microbiology, Reproductive & Genetic, Transplantation, Livestock and Agriculture, Forensics, and Research and Development. Advancement in genomics has greatly contributed to development of candidate gene approach and it is one of the most commonly used techniques to identify genes underlying disease traits. More recently, with genomic resources accessible through public Web, DigiCGA (Digital Candidate Gene Approach) have come as a new development in this field. DigiCGA, is an approach that is still in nascent stage but has already achieved some primary success in cancer gene discovery. The predictive analysis through digital genome has started being used widely. This will contribute to digital genome market growth.

The Diagnostics & Forensic Labs segment is anticipated to hold a majority of the Digital Genome Market size throughout the study period.

Based on end-use. It is segmented into Diagnostics & Forensic Labs, Academic Research Institutes, Hospitals, and Bio-Pharmaceutical Companies. Forensic labs are using next-generation sequencing technologies such as Illumina sequencing by synthesis (SBS) for high performance and error-free results. They also use PCR and capillary electrophoresis- based methods widely for DNA testing. National DNA database aids in investigation and identification of suspects, owing to this various country are trying to establish criminal intelligence databases that resulted in increased number of samples for DNA processing. Due to wide range of applications of digital genomics such as identification of missing persons, ancestry investigations, kinship testing and human identification demand for digital genomics is expected to increase by forensic labs.

The North America region is estimated to exhibit the highest growth rate during the Digital Genome Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the market with a revenue share of over xx% in 2022, which is attributed to increased investments in artificial intelligence and neural networks. The genomic industry in U.S is still in its growing phase and is expected to grow at a fast pace in the coming years. The availability of new genome sequencing technologies, well-established healthcare infrastructure, increasing geriatric population are contributing towards revenue growth of market. Demand for precision medicines is rising in the country. Furthermore, in 2018 FDA has approved various drugs such as Lynparza & Blincyto that are tailored to specific characteristics of an individual. Genes are responsible for cause of many rare genetic disorders such as hutchinson-gilford progeria, psoriasis, cystic fibrosis, Rett’s syndrome, etc. These diseases are affecting about 25 million people in United States. Researchers are using genomics to treat such genetic disorders by innovating new precision medicines and early diagnosis tools. Hospitals in the U.S. are also using genomics in detection and treatment of cancer. The biotechnology and pharmaceutical sectors in the U.S are marked by rapid growth that can further have positive impact of genomics market. The cost of sequencing genome is reducing and awareness among the people about importance of sequencing is rising, that will significantly propel growth of genomics in the country.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10511/

Competitive Landscape

The key players in the Digital Genome Market Agilent Technologies, Inc., Becton Dickinson, Pacific Biosciences, Perkin Elmer, Sigma Aldrich and Thermo Fisher, among others.

Recent Developments in the Digital Genome Market:

  • In May 2022, Gencove, one of the leading low-pass whole genome sequencing and analysis software companies, along with NEOGEN Corporation, launched the InfiniSEEK, a revolutionary, cost-effective solution for whole genome sequencing and targeted SNP analysis from two trusted leaders in genomics.
  • In March 2022, LetsGetChecked, a leading healthcare solutions company, acquired Veritas Genetics Inc. and Veritas Intercontinental, pioneers in genomics that share a scalable platform enabling the rapid interpretation of genetic information from a single gene to the whole genome. The strategic move signifies a crucial advancement in LetsGetChecked’s mission to empower individuals to take control of their health and enable both consumers and healthcare partners to be more proactive in healthcare management.

Digital Genome Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Digital Genome Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Digital Genome Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Digital Genome Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Digital Genome Market Segmentation

By Product

  • Sequencing & Analyzer Instruments,
  • DNA/RNA Analysis Kits
  • Sequencing Chips
  • Sequencing & Analysis Software
  • Sample Preparation Instruments

By Application

  • Microbiology
  • Reproductive & Genetic
  • Transplantation
  • Livestock and Agriculture
  • Forensics
  • Research and Development

By End-user

  • Diagnostics & Forensic Labs
  • Academic Research Institutes
  • Hospitals
  • Bio-Pharmaceutical Companies

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Agilent Technologies, Inc
  • Becton Dickinson
  • Pacific Biosciences
  • Perkin Elmer
  • Sigma Aldrich
  •  Thermo Fisher Scientific
  • Qiagen
  •  F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • GenMark Diagnostics, Inc.
Read More

RNAi Therapeutics Market
February, 2023

RNAi Therapeutics Market to Reach US$ 3.8 Bn by 2032, driven by increasing collaboration activities between drug distribution companies and contract research organizations (CROs): Global Insight Services

New York, January 2023: According to a new research study by Global Insight Services (GIS), the global RNAi Therapeutics Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 3.8 Billion by 2032.

A brand-new class of drugs based on ribonucleic acid is known as RNA therapies (RNA). Target mRNA molecules are neutralized during the biological process known as RNA interference, and RNA molecules are then shown to impede gene expression or translation. Additionally, RNA interference (RNAi) is a group of short RNA-directed processes that inhibits the expression of genes in a sequentially-specific manner.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10510/

RNAi Therapeutics Market: Key Trends and Drivers

Rising cases of chronic diseases

The rising rates of chronic diseases like cancer, cardiovascular conditions, and others will accelerate market expansion. The RNAi therapeutics market will be further fuelled by additional factors such as rising RNAi therapeutic approvals, advancements in the healthcare sector, rising R&D expenditures, and rising pharmaceutical company collaborations during the forecast period.

Increasing collaborative activities

The increasing collaboration activities between drug distribution companies and contract research organizations (CROs) contribute to the growth of the RNAi therapeutics market. Arrowhead Pharmaceuticals Inc and Horizon Therapeutics plc announced a global collaboration and licence agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout, on June 21, 2021. This collaboration with Horizon also represents an expansion of Arrowhead Pharmaceuticals’ rapidly growing pipeline of investigational RNAi therapeutics based on the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform.” In January 2016, Ionis Pharmaceuticals (previously Isis Pharmaceuticals) began a Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals. This acquisition aims to treat Hepatitis B viral infection.

RNAi Therapeutics Market: Restraints & Challenges

High investment and strict regulations

FDA drug approval rates have been declining in recent years. Obtaining FDA approval for a new drug has become extremely difficult. It has approved fewer than half as many new drugs in 2016 (19 so far) as it did in 2015 (45 total) and 2014. (41 total). As a result, despite large investments, the number of innovative drugs manufactured has decreased. The FDA cites manufacturing standards and other compliance issues as the primary causes of this downward trend. This can hamper the growth of RNAi therapeutics, especially since miRNAs and siRNAs fall into the relatively new field of genetic medicine, which may necessitate more intensive clinical trials.

This RNAi therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the RNAi therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

RNAi Therapeutics Market Report Findings

https://www.globalinsightservices.com/reports/rnai-therapeutics-market/

The small-interfering RNA (siRNA) segment is likely to hold a dominant RNAi Therapeutics Market share and grow at a substantial CAGR during the forecast period.

By type, the market is segmented into Small Interfering RNAS, and Microrna. The small-interfering RNA (siRNA) segment held the largest revenue share of in 2021. Small-interfering RNA (siRNA), synthetic double-stranded RNA consisting of approximately 21 base pairs, suppresses problematic target genes in a sequence-specific manner via inherent RNA interference (RNAi) processing. As a result, siRNA offers a potential strategy for treatment of many human diseases. Small-interfering RNA (siRNA), synthetic double-stranded RNA consisting of approximately 21 base pairs, suppresses problematic target genes in a sequence-specific manner via inherent RNA interference (RNAi) processing. As a result, siRNA offers a potential strategy for treatment of many human diseases.

The Neurodegenerative Disorders segment is anticipated to hold a majority of the RNAi Therapeutics Market size throughout the study period.

By application, the RNAi Therapeutics Market is classified into Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurodegenerative Disorders, Genetic Disorders, and Others. Neurodegenerative Disorders segment accounted for xx USD Billion revenue in 2021. Advancements in technologies, such as NGS and microarray, are major drivers of the industry. The decline in sequencing prices has driven attention to the testing of rare diseases. In addition, the rising demand for early & rapid diagnosis is expected to foster the growth of the market. Furthermore, the critical role of translational research & genomic technologies to enhance the analysis and identification of novel mutations is expected to contribute to the industry growth. With more translational research activities in this area, the implementation of genetic testing in disease diagnostics is anticipated to witness high growth during the forecast period.

The Pulmonary Delivery segment is anticipated to hold a majority of the RNAi Therapeutics Market size throughout the study period.

The Route of Administration, it is segmented into Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, and Others. As per the data published by the Global Asthma Network (GAN) in “The Global Asthma Report 2014”, asthma affects nearly 334 million people worldwide. The substantial increase in prevalence and incidence of respiratory diseases has led to an increase in the patient population, which has in turn increased the demand for these systems. This consequent increase in demand is estimated to drive growth over the coming years.

The North America region is estimated to exhibit the highest growth rate during the RNAi Therapeutics Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to dominate the market. This is due to the high usage of antisense and RNAi therapeutics such as Spinraza offered by Biogen Inc., Onpattro and Givlaari offered by Alnylam Pharmaceuticals, Inc., and others in the region. In addition, other factors that contribute to the growth of the market in the region include the availability of advanced antisense and RNAi therapeutics. Furthermore, the presence of well-established healthcare infrastructure in the region leads to a surge in early screening of rare diseases which in turn leads to a surge in demand for antisense and RNAi therapeutics. For instance, Cure SMA is a non-profit organization dedicated to promoting and supporting research related to spinal muscular atrophy. Furthermore, in June 2021, Cure SMA reported that 85% of newborns in the United States were screened for spinal muscular atrophy.

In addition, in August 2022, Cure SMA announced the addition of 9 new spinal muscular atrophy screening centers to its Care Center Network. In addition, currently, there are 27 such care centers in this network across the United States. Thus, this leads to a surge in early screening in the region which in turn leads to a surge in demand for antisense and RNAi therapeutics. Therefore, owing to the previously mentioned factors the growth of the market studied is anticipated in the North America Region.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10510/

Competitive Landscape

The key players in the RNAi Therapeutics Market BroadcomESET North AmericaIBM CorporationIntel CorporationMcAfee, LLCMicrosoftSophos Ltd.Thales GroupTrend Micro Incorporated and WinMagic, among others..

Recent Developments in the RNAi Therapeutics Market:

  • In December 2021, Novartis AG received Food and Drug Administration (FDA) approval for Leqvio (inclisiran). Furthermore, Leqvio is a small interfering RNA (siRNA) therapy approved for lowering low-density lipoprotein cholesterol (LDL).
  • In December 2021, AstraZeneca plc and Ionis Pharmaceuticals entered into global development and commercialization agreement for eplontersen, an antisense investigational medicine. Furthermore, eplontersen is currently being studied in phase II of clinical trials for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PN).
  • In July 2021, Alnylam Pharmaceuticals, Inc. and PeptiDream Inc. entered into a licensing and collaboration agreement. Furthermore, the agreement is aimed at the discovery and development of peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver.

RNAi Therapeutics Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global RNAi Therapeutics Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future RNAi Therapeutics Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the RNAi Therapeutics Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global RNAi Therapeutics Market Segmentation

By Type

  • Small Interfering RNAS
  • Microrna

By Application

  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Neurodegenerative Disorder
  • Genetic Disorders
  • Others

By Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intra-dermal Injections
  • Intraperitoneal Injections
  • Topical Delivery
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Quark Software Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Rexahn Pharmaceuticals, Inc. (U.S.)
  • Silence Therapeutics (U.K.)
  • Arbutus Biopharma (U.S.)
  • Benitec Biopharma (Australia)
  • GSK plc (U.K.)
  • OLIX PHARMACEUTICALS, INC. (South Korea)
  • Sanofi (France)
  • Alnylam Pharmaceuticals, Inc. (U.S.)
  • Moderna Inc. (U.S.)
  • Ionis Pharmaceuticals (U.S.)
Read More

Medical Enzyme Technology Market
January, 2023

Medical Enzyme Technology Market to Reach US$ 7.7 Bn by 2032, driven by the rising utilization of enzymes in biotech, as well as medical research: Global Insight Services

New York, January 2023: According to a new research study by Global Insight Services (GIS), the global Medical Enzyme Technology Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 7.7 Billion by 2032.

Enzymes play a crucial role in the metabolic activities of all organisms, whether animal, human, plant, or microbial. They have an extensive range of applications in microbial biotechnology and diagnosis processes. The abnormality of the enzyme metabolism system leads to many metabolic diseases. Further, enzymes can be used as medicines to treat a range of diseases; they are called medicinal enzymes. For example, trypsin can be used not only to accelerate wound healing and dissolve blood clots but also to remove necrotic tissue and inhibit the proliferation of contaminating microorganisms. L-asparaginase can be used to treat cancer by depriving nutrients needed by the growth of cancer cells. Protease (like multi-enzyme tablets) can be used to treat dyspepsia, and it has an anti-inflammatory effect. Moreover, lipase, superoxide dismutase, nattokinase, soybean meal plasmin, and thrombin, among others, can be used to treat diseases.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10508/

Medical Enzyme Technology Market: Key Trends and Drivers

Rising demand for low cost and affordable, yet effective medical treatments, as well as rising prevalence of cancer, is estimated to fuel growth within the global medical enzyme technology market in coming years. Furthermore, rising focus of market players on research and development, as well as growing public awareness regarding benefits of these advanced treatment solutions is positively impacting growth within the global medical enzyme technology market.

Medical Enzyme Technology Market: Restraints & Challenges

The key restraints and challenges in Medical Enzyme Technology market are as follows:

Enzymes present some challenges, such as short in vivo half-life, lack of targeted action and, in particular, patient immune system reaction against the enzyme. For this reason, it is important to monitor serum immune response during treatment.

Medical Enzyme Technology Market Report Findings

https://www.globalinsightservices.com/reports/medical-enzyme-technology-market/

The hydrolase segment is likely to hold a dominant Medical Enzyme Technology Market share and grow at a substantial CAGR during the forecast period.

Based on Enzyme, the market is segmented as Digestive Enzyme, Thrombolytic Enzyme, Hydrolases, and Others. The hydrolase segment held the largest revenue share of over xx% in 2022 Hydrolase enzymes possess the ability to accelerate the substrate’s breakage. They also feature excellent catalyst effectiveness, broad specificity for substrates, are widely and commercially available, and showcase excellent stability. The hydrolases enzymes aid in treatment of several kind of disorders. Owing to their excellent properties, hydrolases enzyme products are expected to lead the global medical enzyme technology market in terms of demand in coming years.

The diagnostic tools segment is anticipated to hold a majority of the Medical Enzyme Technology Market size throughout the study period.

Based on application, the market is segmented as Disease Treatment, Diagnostic Tools, and Biomedical Research. The diagnostic tools segment accounted for the largest revenue share of over xx% in 2022. Products in the global medical enzyme technology market are widely used across diagnostic and pharmaceutical sectors. They are most commonly used as therapeutic agents in treatment of several disorders, most prominently ones caused by shortage of enzymes in the body. Furthermore, they are also used in various biotechnological, as well as diagnostic procedures, including sequencing and modification of DNA. Medical enzymes are also used in manufacture of several diagnostic testing solutions, such as ELISA.

The Asia-Pacific region is estimated to exhibit the highest growth rate during the Medical Enzyme Technology Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Asia Pacific is projected to display significant growth in the global medical enzyme technology market in coming years. Growing awareness amongst public, milestone achievements in biotechnology research, and growing acceptance of new technologically advanced solutions and advancements in medical technology, are some of the key drivers for this market. Furthermore, growing pharmaceutical output of the regional pharmaceutical manufacturers is also favoring growth within the Asia Pacific medical enzyme technology market.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10508/

Competitive Landscape

The global Medical Enzyme Technology Market report includes players such as Merck KGaA, Thermo Fisher Scientific Inc., Novozymes, Takeda Pharmaceutical Company Limited, Agilent Technologies, Inc., Genzyme Corporation, Asahi Kasei Corporation, Promega Corporation, Cytiva, and Amano Enzyme Inc ., among others.

Recent Developments in the Medical Enzyme Technology Market:

  • In December 2022, Ginkgo Bioworks announced the launch of Ginkgo Enzyme Services. Ginkgo Enzyme Services is powered by ultra-high throughput screening and machine learning-guided protein design, as well as optimized proprietary bacterial and fungal host strains.
  • In January 2020, Curative Enzymes, a product and service provider, launched the enzyme engineering and modification service to help major clients.
  • In April 2019, DuPont Nutrition & Biosciences has launched OPTIMASE, a new portfolio of biobased enzymes for medical instrument cleaning applications. The new range has been designed to deliver optimal cleaning performance in medical instrument cleaning applications while helping customers optimise formulation costs.

Medical Enzyme Technology Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Medical Enzyme Technology Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Medical Enzyme Technology Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Medical Enzyme Technology Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Medical Enzyme Technology Market Segmentation

By Enzyme

  • Digestive Enzyme
  • Thrombolytic Enzyme
  • Hydrolases
  • Others

By Application

  • Disease Treatment
  • Diagnostic Tools
  • Biomedical Research

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • MERCK KGaA
  • THERMO FISHER SCIENTIFIC INC.
  • Novozymes
  • Takeda Pharmaceutical Company Limited
  • Agilent Technologies, Inc.
  • Genzyme Corporation
  • Asahi Kasei Corporation
  • Promega Corporation
  • Cytiva
  • Amano Enzyme Inc.

 

Read More

Cell Culture Media Market
January, 2023

Cell Culture Media Market to Reach US$ 12.7 bn by 2032, driven by the growing demand for biopharmaceuticals, favorable governmental policies, and increasing investment in R&D

New York, December 2022: According to a new research study by Global Insight Services (GIS), the global Cell Culture Media Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 12.7 bn by 2032.

Cell culture media is generally a gel or liquid including compounds required to regulate and support the growth of cells or microorganisms used in the manufacturing of biopharmaceuticals. Culture media is a critical ingredient in biopharmaceutical manufacturing, aiding the growth of cells, and is the fastest-growing segment within the cell culture market.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS20880/

Cell Culture Media Market: Key Trends and Drivers

The expansion of clear, regulatory approval paths for biosimilars in emerging markets is generating more opportunities for biosimilar monoclonal antibodies. Moreover, the reduction of manufacturing costs has become one of the most significant technological advantages for a biosimilar manufacturer. Therefore, the capability to imitate the biologically active molecule at the lowermost possible cost via cell culture has become important for efficient biosimilar development. In the last few years, stem cell therapy has become an advanced and promising scientific research area. The development of treatment methods has induced great opportunities. Moreover, there is growing interest in improving the stem cell culture, because this technology is being used extensively in research for studying the stem cell biology, as well as for therapeutic applications. In addition, funding related to this research filed has augmented in recent years which has further accelerated the growth of research.

Cell Culture Media Market: Restraints & Challenges

Cell culture media is a complex mixture of nutrients, growth factors, hormones, and other factors that are essential for the growth and maintenance of cells in vitro. The composition of cell culture media is carefully balanced to support the specific needs of the cells being cultured. One of the key challenges in cell culture media is the lack of standardization. There is no one-size-fits-all cell culture media, and each cell type has specific nutritional requirements. This can make it difficult to compare results from different laboratories and to replicate experiments. Another challenge is the cost of cell culture media. Cell culture media is typically more expensive than other types of media, such as tissue culture media, because it is more complex and often contains more expensive ingredients.

Cell Culture Media Market Report Findings

https://www.globalinsightservices.com/reports/cell-culture-media-market/

The Liquid Media segment is anticipated to hold a majority of the Cell Culture Media Market size throughout the study period.

Based on the type, the Cell Culture Media market is divided into liquid media, and semi-solid and solid media. Of these, the liquid media segment captured the highest revenue share of xx% in 2022. An increasing number of biologics and biosimilars manufacturers, both downstream and upstream, are switching from premixed powders to liquid media owing to the factors such as rapid mycobacterial growth and high rate of isolation. Moreover, it eradicates a few process steps, and also reduces the probability of hazardous exposure, and makes manufacturing and development more flexible and simpler than powdered media. In addition, ready-to-use liquid media also eliminates the need for mixing containers, balances, and installation of water for injection (WFI) loop which is needed for mixing powder media. The segment is also being driven by the strategic activities of the manufacturers, for instance, in June 2021, Sartorius, opened its new site in Israel, which focuses on customized and specialty cell culture mainly for the advanced therapies market. This site will serve as a significant production site for buffers and liquid cell culture.

The Serum-free Media segment is anticipated to hold a majority of the Cell Culture Media Market size throughout the study period.

By product, the industry is bifurcated into Serum-free Media, Classical Media, Stem Cell Culture Media, Specialty Media, Chemically Defined Media, Others. The SFM segment held the highest revenue share of xx% in 2022. The use of SFM signifies a significant tool, which allows the researchers to perform specific application or grow a specific cell type without using serum. Advantages of using SFM include increased growth and/or productivity, more consistent performance, better control over physiological sensitivity, and to diminish the risk of infection by serum-borne adventitious agents in the culture. In addition, serum-free alternatives better serve the animal welfare which is the major factor driving the adoption of SFM. In addition, the field of gene and cell therapy is rapidly growing, and the Food and Drug Administration regulatory guidelines are demanding more control of raw materials to sustain the reliable and safe manufacturing of drug products. The use of SFM offers an opportunity to produce additional reproducible formulations and fewer batch-to-batch variability.

The biopharmaceutical production segment is likely to hold a dominant Cell Culture Media Market share and grow at a substantial CAGR during the forecast period.

Based on application, the industry is categorized into biopharmaceutical production, diagnostics, drug screening and development, tissue engineering and regenerative medicine, and others. The biopharmaceutical production segment dominated the market with a share of xx% in 2021. The biopharmaceutical industry’s demand for more reproducible and better-defined media to meet the expanding production levels while reducing the risk of contamination in the downstream processes is significantly increasing the demand for this market. Moreover, strategic activities by key biopharmaceutical companies also drive the segment growth. For instance, in July 2021 Cytiva and Pall Corporation invested USD 1.5 billion for over two years to meet the rising demand for biotechnology solutions. The two companies plan to invest USD 400+ million for culture media in powder or liquid along with expanding its operations in the U.S., Austria, and U.K..

The Pharmaceutical And Biotechnology Companies segment is anticipated to hold a majority of the Cell Culture Media Market size throughout the study period.

Based on end-user, the Cell Culture Media market is divided into Pharmaceutical And Biotechnology Companies, Hospitals And Diagnostic Laboratories, Research And, Academic Institutes, and Others. The pharma and biopharma companies segment captured the highest revenue share of 34.2% in 2021. The expansion of the current manufacturing capacities for biopharmaceuticals drives the demand for cell culture products. For instance, in September 2020, Cytiva, announced the expansion of its manufacturing capacity and hiring personnel in significant areas to support the growth of the biotechnology industry. The company has planned investment of around USD 500 million for five years to increase the manufacturing capacity. In addition, increasing clinical trials will further offer lucrative opportunities in the review period. For instance, in 2021, the number of industry-sponsored trials in progress for regenerative medicine augmented by 100 as compared to 2020, bringing the total to 1,320. There were 1,328 regenerative medicine trials in progress worldwide supported by non-industry groups such as government entities and academic centers.

The Asia-Pacific region is estimated to exhibit the highest growth rate during the Cell Culture Media Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. In Asia Pacific, the market is estimated to grow fast owing to the increase in awareness associated with the use of the cell culture technique. Furthermore, strategic activities by key players to expand their presence in the Asia Pacific countries to capture high market share is expected to offer lucrative opportunities. For instance, In December 2021, Fujifilm Irvine Scientific, Inc., in China started the construction to build its new bioprocessing center, with the aim to ensure cell culture media optimization support for biotherapeutic drug development, vaccines, and advanced therapies.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS20880/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Cell Culture Media market include Avantor Performance Materials, LLC, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Corning Incorporated, Fujifilm Holdings Corporation, GE Healthcare, HiMedia Laboratories Pvt., Ltd, Lonza Group Ltd. and Merck & Co., Inc. among others.

Recent Developments in the Cell Culture Media Market:

  • In December 2021, Fujifilm Irvine Scientific, Inc., in China started the construction to build its new bioprocessing center, with the aim to ensure cell culture media optimization support for biotherapeutic drug development, vaccines, and advanced therapies.
  • In July 2021, Sartorius, through its subsidiary Sartorius Stedim Biotech, acquired the cell culture expert Xell AG. The company develops, produces, and markets feed supplements and media for cell cultures, particularly for the manufacturing of viral vectors that are used in vaccines and gene therapeutics
  • In July 2021 Cytiva and Pall Corporation invested USD 1.5 billion for over two years to meet the rising demand for biotechnology solutions. The two companies plan to invest USD 400+ million for culture media in powder or liquid along with expanding its operations in the U.S., Austria, and U.K.
  • In June 2021, Sartorius, opened its new site in Israel, which focuses on customized and specialty cell culture mainly for the advanced therapies market. This site will serve as a significant production site for buffers and liquid cell culture.
  • In September 2020, Cytiva, announced the expansion of its manufacturing capacity and hiring personnel in significant areas to support the growth of the biotechnology industry. The company has planned investment of around USD 500 million for five years to increase the manufacturing capacity.

Cell Culture Media Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Cell Culture Media Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Cell Culture Media Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Cell Culture Media Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Cell Culture Media Market Segmentation

By Type

  • Liquid Media
  • Semi-solid And Solid Media

By Product

  • Serum-free Media
  • Classical Media
  • Stem Cell Culture Media
  • Specialty Media
  • Chemically Defined Media
  • Others

By Application

  • Biopharmaceutical Production
  • Diagnostics
  • Drug Screening And Development
  • Tissue Engineering And Regenerative Medicine
  • Others

By End-user

  • Pharmaceutical And Biotechnology Companies
  • Hospitals And Diagnostic Laboratories
  • Research And Academic Institutes
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Avantor Performance Materials, LLC
  • Becton
  • Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • Corning Incorporated
  • Fujifilm Holdings Corporation
  • GE Healthcare
  • HiMedia Laboratories Pvt.Ltd
  • Lonza Group Ltd.
  • Merck & Co., Inc.

 

Read More